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ABSTRACT
Viral vectors can be utilised to deliver therapeutic genes to diseased cells. Adeno-associated virus (AAV) is a commonly
used viral vector that is favoured for its ability to infect a wide range of tissues whilst displaying limited toxicity and immu-
nogenicity. Most humans harbour anti-AAV neutralising antibodies (NAbs) due to subclinical infections by wild-type
virus during infancy and these pre-existing NAbs can limit the efficiency of gene transfer depending on the target cell
type, route of administration and choice of serotype. Vector administration can also result in de novo NAb synthesis that
could limit the opportunity for repeated gene transfer to diseased sites. A number of strategies have been described in
preclinical models that could circumvent NAb responses in humans, however, the successful translation of these innova-
tions into the clinical arena has been limited. Here, we provide a comprehensive review of the humoral immune response
to AAV gene therapy in the ocular compartment. We cover basic AAV biology and clinical application, the role of pre-
existing and induced NAbs, and possible approaches to overcoming antibody responses. We conclude with a framework
for a comprehensive strategy for circumventing humoral immune responses to AAV in the future.
Key words: AAV, gene therapy, retina, ocular, neutralizing antibodies, immune response
CONTENTS
I. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1617
II. Successes in aav clinical trials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1617
III. Immune responses to aav – key considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1618
(1) How are immune responses initiated? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1618
(2) Is AAV non-pathogenic and non-immunogenic? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1618
(3) Innate immune responses to AAV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1619
(4) Cellular immune responses to AAV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1619
(a) Pre-existing cellular immunity to AAV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1620
(b) Induction of anti-AAV cellular immune responses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1620
IV. Humoral immune responses to aav . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1621
(1) How are antibodies produced? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1621
(2) How do antibodies neutralise AAV? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1621
(3) Pre-existing humoral immunity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1622
(4) Induction of anti-AAV humoral immune responses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1623
(a) Gene therapy trials targeting the liver and skeletal muscle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1623
* Address for correspondence (Tel: +447983364605; E-mail: mw684@cam.ac.uk)
Biological Reviews 96 (2021) 1616–1644 © 2021The Authors. Biological Reviews published by JohnWiley & Sons Ltd on behalf of Cambridge Philosophical Society.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
Biol. Rev. (2021), 96, pp. 1616–1644. 1616
doi: 10.1111/brv.12718
(b) Gene therapy trials targeting the central nervous system . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1623
(c) Gene therapy trials targeting the eye . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1624
(i ) Gene delivery to the outer retina by subretinal injection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1625
(ii ) Gene delivery to the inner retina by intravitreal injection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1626
(iii ) Is the eye immune-privileged with respect to AAV gene therapies? . . . . . . . . . . . . . . . . . . . . . . . . . . . 1628
V. Possible strategies to circumvent humoral immunity to aav . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1630
(1) Overcoming pre-existing AAV NAbs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1630
(a) Altering the route of administration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1630
(b) Use of alternative AAV vectors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1630
(c) Chemical modification of AAV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1632
(d) Use of decoy capsids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1633
(e) Plasmapheresis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1633
(f ) Use of pharmacological immunosuppressants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1634
(g) Use of NAb degrading enzymes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1634
(2) Preventing the induction of AAV NAbs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1634
(a) Inhibition of T-cell activation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1634
(b) Inhibition of B-cell activation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1635
(c) Use of pharmacological immunosuppressants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1636
(3) Overcoming humoral immune responses to AAV – the need for a comprehensive approach . . . . . .1637
VI. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1639
VII. References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1639
I. INTRODUCTION
Adeno-associated virus (AAV) is a non-enveloped Parvovirus
that was originally identified as a contaminant in adenoviral
cultures (Hastie & Samulski, 2015). The virus exhibits a
T = 1 icosahedral shape with a 25 nm diameter
(Srivastava, Lusby & Berns, 1983). AAV capsid proteins con-
tain a single-stranded DNA (ssDNA) genome (Rose
et al., 1969) flanked by inverted terminal repeats (ITRs)
(McLaughlin et al., 1988). Transcription mapping of the
genome of AAV2 reveals three overlapping messenger
RNA (mRNA) molecules that are produced from three pro-
moters: p5, p19 and p40 (Laughlin, Westphal &
Carter, 1979). The p5 and p19 promoters are known to
mediate expression of rep genes required for AAV DNA rep-
lication and packaging of genetic cargo into AAV particles
(Im & Muzyczka, 1990), whereas the p40 promoter drives
transcription of cap gene mRNA, which is alternatively
spliced to yield three distinct protein products, VP1, VP2
and VP3 in a 1:1:10 ratio (Becerra et al., 1988). p40 also
mediates expression of assembly-activating protein (AAP) in
a different open reading frame (ORF) (Samulski &
Muzyczka, 2014). AAP is not present in mature AAV capsids,
but is known to play a key role in enabling production of
high-titre AAV preparations for certain serotypes (Maurer
et al., 2018).
To produce recombinant AAV (rAAV) for gene therapy,
the rep/cap genes are removed and replaced with a therapeu-
tic gene and a promoter sequence to drive expression. The
maximum size of a genetic sequence that can be cloned/
synthesised between the ITRs is around 4.7 kbp, which limits
the application of AAV in diseases requiring the delivery of
large gene expression cassettes exceeding this capacity (Wu,
Yang & Colosi, 2010). When rAAV genomes enter the cell
nuclei, second-strand synthesis occurs that converts a linear
ssDNA molecule into a double-stranded DNA (dsDNA) epi-
some, thus enabling the synthesis of therapeutic constructs
(Choi, McCarty & Samulski, 2006). Achieving nuclear trans-
fer of AAV genetic cargo is a complex multistep process,
however. First, the virus must bind to a cell and undergo
endocytosis by utilising a number of primary receptors and
co-receptors, many of which have not yet been identified
(Pillay et al., 2016). AAV then ‘escapes’ from the endosome
as it acidifies and it is thought to be trafficked to the nucleus
via a nuclear localisation sequence (NLS) on the VP1 and
VP2 capsid monomers (Xiao & Samulski, 2012). Recent
studies have shown that nuclear import of rAAV is mediated
by nuclear pore complexes (NPCs) and this process is depen-
dent upon interactions with importin-α (Kelich et al., 2015).
After nuclear import, rAAV capsids uncoat, thereby releas-
ing their genetic cargo into the target cell (Berry &
Asokan, 2016).
II. SUCCESSES IN AAV CLINICAL TRIALS
A number of successful clinical trials have now demonstrated
the potential for using AAV as a gene transfer device for ther-
apeutic purposes. AAV is an attractive vector for human
gene therapy benefitting from several advantages. First, it is
largely non-integrating, thereby reducing the risk of inser-
tional mutagenesis via the disruption of tumour suppressor
genes, which is a major concern for lentiviral gene therapies,
for example (Moiani et al., 2012). Second, AAV can be used
to target a very broad range of cell types as a number of dif-
ferent serotypes exist, each with a unique tissue tropism
(Srivastava, 2016). Whilst the packaging capacity of AAV is
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relatively limited, it is thought to induce transgene expression
in both dividing and non-dividing cells (Colella, Ronzitti &
Mingozzi, 2018). Finally, although there is an emerging body
of evidence implicating a negative impact of humoral and
cellular immune responses on AAV-mediated gene transfer,
AAV is largely considered a safe vector for human gene ther-
apy, especially when delivered locally close to the site of
pathology, such as the vitreous cavity of the eye (Khabou
et al., 2018).
At the time of writing, three gene therapy programmes
have demonstrated efficacy in phase III studies. Zolgensma
(onasemnogene abeparvovec-xioi) was approved by the
USA FDA in 2019 for the treatment of spinal muscular atro-
phy (SMA) in patients harbouring biallelic mutations in the
smn1 gene. The therapy utilises the AAV9 serotype, which
is unique in its ability to cross the blood–brain barrier
(BBB), to deliver circular DNA (cDNA) encoding the smn1
gene under control of the CAG promoter (Shahryari
et al., 2019). In one study, participants demonstrated remark-
able improvements in motor function and quality of life, with
11/12 patients achieving full head control and two patients
even walking independently (Rao, Kapp & Schroth, 2018;
Al-Zaidy et al., 2019). Luxturna (voretigene neparvovec) is
an AAV2-based gene therapy for Leber’s Congenital Amau-
rosis type 2 (LCA2). LCA2 is caused by biallelic (homozy-
gous or compound heterozygous) mutations in the retinal
pigment epithelium-65 (rpe65) gene, which encodes a critical
enzyme essential for visual processing by converting all-
trans-retinyl esters to 11-cis-retinol during phototransduc-
tion (Cremers, 2002). In an open-label, randomised phase
III study, no therapy-related serious adverse events or unac-
ceptable immune responses occurred, whilst 65% of treated
patients demonstrated improvements in visual function
(Russell et al., 2017). Further assessment has corroborated
the safety of the approach, demonstrating that Luxturna
can deliver benefits to patients up to four years after admin-
istration (Maguire et al., 2019). In summary, the successful
gene therapy programme for LCA2 illustrates the merits of
AAV-mediated gene delivery to the outer retina by subret-
inal injection, providing the impetus for other programs tar-
geting disorders affecting photoreceptors and retinal
pigment epithelium (RPE). Programs targeting the inner ret-
ina, and specifically the retinal ganglion cell (RGC) layer,
have also demonstrated promising results for the ameliora-
tion of genetic disease. Lenadogene (GS010) is an
AAV2-based treatment for Leber’s Hereditary Optic Neu-
ropathy (LHON), which is is the most common cause of
mitochondrial blindness, affecting at least 1 in 35000 of the
population. Themajority of patients carry one of three mito-
chondrial DNA (mtDNA) point mutations (m.3460A>G in
MTDN1, m.11778G>A in MTND4, and m.14484T>C in
MTND6), which all affect genes encoding subunits of the
mitochondrial respiratory chain complex I (Yu-Wai-Man
et al., 2014). In a phase III study, Lenadogene treatment
resulted in improvements in best-corrected visual acuity
(BCVA) with an increase of 26 Early Treatment Diabetic
Retinopathy Study (ETDRS) letters in the treated eyes at
96 weeks following intravitreal injection, which is greater
than expected from the natural history of LHON (Yu-Wai-
Man, Moster & Sadun, 2019). Further, a secondary analysis
of a phase I/II trial of patients receiving Lenadogene
showed the treatment was safe and well tolerated, withmostly
mild and transient intraocular inflammation in the anterior
chamber and vitreous (Bouquet et al., 2019). Overall, whilst
Lenadogene is yet to obtain regulatory approval, the trials
demonstrate the potential of AAV-mediated gene transfer to
the inner retina. However, the unexpected observation that
unilateral intravitreal injections given to patients resulted in
improvements in visual acuity in the contralateral (untreated)
eye is something that warrants further investigation (Yu-Wai-
Man et al., 2019).
III. IMMUNE RESPONSES TO AAV – KEY
CONSIDERATIONS
(1) How are immune responses initiated?
Anorganismmounts an immune response to protect themselves
against foreign protein structures, termed antigens, that may be
detrimental to their survival. Immune responses can be classi-
fied as innate or adaptive. In an innate immune response,
pathogen-associated molecular patterns (PAMPs) are recog-
nised by pattern recognition receptors (PRRs). This drives a
rapid and non-specific response that does not induce any immu-
nological memory (Mogensen, 2009). During a wild-type AAV
infection, PRRs can recognise viral nucleic acids and mem-
brane glycoproteins, which leads to nuclear factor κB (NFκB)
and interferon regulatory factor (IRF) activation and synthesis
of proinflammatory cytokines and type I interferons respectively
(Vandamme, Adjali & Mingozzi, 2017). Adaptive immunity
arises after the innate immune response and results in the devel-
opment of ‘immunological memory’, which allows the organ-
ism to mount a faster and more efficient immune response
when encountering the antigen for the second time. Adaptive
immunity begins with the presentation of a particular antigen
by an antigen presenting cell (APC) to T and B lymphocytes.
These cells are then activated, and undergo clonal expansion
(proliferation of T and B cells that are specific to the particular
antigen that has been recognised). This is followed by T and B
cell differentiation into effector cells [CD4+ or CD8+ T-cells,
or plasma cells (PCs)] which act to eliminate the antigen via
the destruction of virally infected cells or de novo antibody synthe-
sis (Cui & Kaech, 2010; Pennock et al., 2013; Tellier &
Nutt, 2019). Finally, a population of memory T and B cells
remain which are able to recognise the antigen rapidly if the
organism encounters it a second time (Dorak, 2002).
(2) Is AAV non-pathogenic and non-immunogenic?
Until recently, wild-type AAV was not generally considered
to be associated with any known human pathology. This is
considered a key factor given that up to 90% of people are
thought to be asymptomatically infected with AAV
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throughout their lifetimes (Kruzik et al., 2019). However,
recent evidence has suggested a role for wild-type AAV2 in
the development of hepatocellular carcinoma (HCC). The
authors observed AAV2 genome integration in 11/194
HCC samples tested, and concluded that wild-type AAV2
may have been a causative factor via oncogenic insertional
mutagenesis (Nault et al., 2015). It should be emphasised
however, that their findings related to wild-type AAV2 and
in later publications, the authors clarified that their findings
should not be confounded with the clinical use of rAAV gene
therapies (Nault et al., 2016). Given the inherent similarities
between wild-type AAV2 and rAAV2 however, more
research into the possibility of oncogenic genome insertion
is needed.
A key factor underpinning the progress of AAV-based
gene therapy into the clinic is the safety profile of the vector.
Depending on the route of administration, choice of serotype
and dosage used, rAAV exhibits a relatively tolerable safety
profile when compared to other gene transfer devices like
adenovirus and lentivirus (Nayak & Herzog, 2010). A num-
ber of theories have been suggested to explain why wild-type
and rAAV appear to be relatively non-immunogenic. First,
most AAV serotypes may be poor transducers of professional
APCs, such as dendritic cells, and may only result in minimal
upregulation of major histocompatibility complex (MHC; a
key molecular player in the presentation of antigens to the
immune system) proteins in target cell types. This has been
demonstrated in a number of publications investigating
immune-competent sites like the liver and muscle (Mays
et al., 2014; Rossi et al., 2019), however, there is little literature
to support this claim in sites generally considered more
immune-privileged, like the eye and central nervous system
(CNS). A second theory suggests that a lack of viral DNA in
rAAV vectors reduces recognition by PRRs. Whilst the
removal of rep and cap genes from rAAV particles obviates
the in vivo proliferation of the virus, thereby avoiding amplifi-
cation of capsid antigens, this theory does not explain why
rAAV is less immunogenic than adenoviral vectors, for
example, which also have the genes required for capsid rep-
lication removed. One possible explanation for the differ-
ences in immunogenicity observed between AAV and
adenoviral vectors is that AAV transduction induces lower
and more transient innate immune activation (Wold &
Toth, 2014).
(3) Innate immune responses to AAV
Innate immune responses against AAV have recently been
implicated as a possible cause for the toxicities that have been
observed in gene therapy clinical trials. Innate immunity can
be driven by anti-capsid and anti-nucleic acid pathways. It is
now recognised that anti-capsid responses are likely derived
via toll-like receptor 2 (TLR2) signalling, which is expressed
on the cell surface (Hösel et al., 2012). TLR9 signalling is
responsible for the recognition of viral DNA sequences, and
endosomal TLR9 has been implicated in the sensing of
unmethylated CpG motifs in dendritic cell types (Rogers
et al., 2017). Further, upregulation of TLR9 has been corre-
lated with improved antigen presentation to the naiive
CD8+ T-cells with MHC class I molecules, and signalling
of this receptor with myeloid differentiating factor
88 (MyD88) has been implicated as a key pathway instigating
immune responses against transgenes in the liver and muscle
(Ashley et al., 2019; Herzog et al., 2019). The interaction
between plasmacytoid dendritic cells (pDCs) and AAV may
be a key factor mediating the efficiency of in vivo gene transfer
in certain organs. Recognition of viral DNA sequences by
TLR9 activates MyD88 and the type I interferon cascasde,
leading to NFκB-dependent cytokine and chemokine pro-
duction in the liver (Jayandharan et al., 2011), an effect that
has been linked to progressive transgenic silencing over time
(Suzuki et al., 2013).
It has been established that the inhibition of key molecular
players in the pathways mediating activation of the innate
immune response can prevent anti-AAV CD8+ cytotoxic
T-cell responses. Here, inhibition of TLR9 and type I inter-
feron signalling has been shown to attenuate anti-AAV2
CD8+ T-cell induction (Rogers et al., 2017), and blockage
of type I interferons with monoclonal antibody therapy has
demonstrated reduced cross-priming of anti-AAV8 CD8+
T-cells by pDCs (Shirley et al., 2020).
Innate immunity against dsRNA molecules was also
recently identified by Shao et al. (2018). Their findings impli-
cated AAV ITR-driven dsRNA synthesis as a cause of type I
interferon expression in transduced hepatocytes and also
demonstrated that inhibition of MDA5 (a cytoplasmic RNA
sensor) improved transgene expression in these cells (Shao
et al., 2018). This study in particular highlights our evolving
understanding of innate immunity against AAV vectors but
also provides a tangible example of how clarifying the molec-
ular mechanisms underpinning AAV immunity can improve
efficacy in preclinical and clinical studies.
The role of natural killer (NK) cells as determinants of
in vivo gene therapy outcome is perhaps less well characterised
than other arms of the immune system, however, one study
has highlighted a possible role for these innate cytotoxic cells
in seronegative individuals. Here, treatment of peripheral
blood mononuclear cells (PBMCs) from seropositive patients
with AAV capsids was associated with induction of an effec-
tor memory CD8+ phenotype (detected via granzyme B
and CD107a degranulation marker expression), whilst
PBMCs from seronegative patients treated with AAV was
correlated with the activation of NK cells (Kuranda
et al., 2018).
(4) Cellular immune responses to AAV
The innate immune response is clearly linked to the develop-
ment of cellular immunity against AAV vectors. Cellular
immunity can be pre-existing (arises before administration
of therapy; likely via asymptomatic infections by wild-type
AAV) or arise de novo from the administration of an AAV gene
therapy.
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(a) Pre-existing cellular immunity to AAV
Pre-existing cellular immunity to AAV is thought to arise
during infancy following a wild-type AAV infection, which
was recently evidenced by flow cytometry analysis demon-
strating a memory T-cell phenotype (i.e. expression of dif-
ferentiation markers) in subjects’ lymphocyte populations.
These memory T-cells expressed interferon-γ (IFNγ),
interleukin-2 (IL2) and tumour necrosis factor-α (TNFα)
and exhibit a cytotoxic phenotype (induce apoptosis of
AAV-infected cells) as demonstrated by expression of
granzyme B and CD107a (Verdera, Kuranda &
Mingozzi, 2020).
Whilst anti-AAV T-cells exhibit high cross-reactivity and
demonstrate responses to a variety of AAV serotypes (Hui
et al., 2015; Kuranda et al., 2018), the exact role of pre-
existing cellular immunity is not well understood, and it is
noted that the patterns of T-cell reactivity to AAV in gene
therapy trials differ from those seen during a typical viral
infection. As Verdera et al. (2020) suggest, this observation
may reflect the fact that the mode of administration of
AAV gene therapies is the injection of a large number of
non-replicating recombinant vectors into the body, which
does not match that of an ongoing viral infection with repli-
cating virions. More research is required to further our
understanding of this aspect of cellular immunity against
AAV which may be useful to inform inclusion and exclusion
criteria in clinical trials, for example.
(b) Induction of anti-AAV cellular immune responses
As discussed above, a cellular immune response is mounted
against AAV antigens following administration when APCs
present immunogenic capsid proteins to cytotoxic CD8+T-
cells via MHC class I. These capsid-specific T-cells are thus
directed against AAV-infected cells and can induce their
apoptosis via cell-mediated cytotoxicity. This effectively
clears AAV-transduced cells and thereby decreases expres-
sion of a particular transgene product (Mingozzi
et al., 2007; Pien et al., 2009). Presentation of viral capsid
proteins on MHC class II can also occur, resulting in the
activation of CD4+ T-cells, which are known to mediate
both cellular and humoral immunity in response to AAV
gene therapy (Chen et al., 2006). CD4+ T-cells mediate a
number of immune processes, but are thought to be critical
mediators of the antiviral response given their role in acti-
vating B-cells to become antigen-synthesising plasma cells,
and in facilitating class switching to immunoglobulin G1
(IgG1) neutralising antibody (NAb) subtypes (Janeway, Tra-
vers & Walport, 2001).
One of the first examples of cellular immunity against
AAV2 in the clinic was seen during haemophilia B gene ther-
apy trials. After an initial intravenous infusion of 2E12 gc
(genome copies)/kg AAV2 carrying a functional copy of the
factor IX (FIX) gene, transgene expression reached levels
around 10% of that seen in healthy controls. After 4 weeks
however, FIX levels decreased to baseline levels in tandem
with an increase in liver transaminase levels in which an
anti-AAV2 capsid T-cell response was implicated (Manno
et al., 2006). Later studies confirmed this CD8+ T-cell
response using enzyme-linked immunoabsorbent spot
(ELISPOT) assays and flow cytometry in response to trans-
duction of the liver, and showed that the T-cell response
was directed against the AAV2 capsid protein (Mingozzi
et al., 2007). In clinical trials investigating intramuscular
delivery however, anti-AAV cellular immune responses have
been observed, yet these have not apparently attenuated
transgene expression in contrast to liver gene transfer studies
(Brantly et al., 2006, 2009). A number of factors may under-
pin these differences, including the serotype used (AAV1
was used in the muscle gene transfer studies cited above),
the route of administration used, the number of viral parti-
cles administered, and the immune status of the enrolled
patients at baseline (i.e. when initially recruited to the study).
Anti-capsid cellular immune responses can clearly have
a detrimental impact on the efficacy of AAV gene therapy.
Anti-transgene cellular responses have also been noted
involving both CD4+ and CD8+ T-cells. As with anti-
capsid CD8+ responses, anti-transgene cellular immunity
can decrease transgene expression of AAV transduced
cells via cell-mediated cytotoxicity mechanisms (Nidetz
et al., 2020). A number of factors have been implicated as
key mediators of anti-transgene cellular immunity, includ-
ing the route of administration, choice of promoter, fre-
quency of CpG-rich sequences, and secretion of the
transgene product (Verdera et al., 2020). In the clinic how-
ever, anti-transgene cellular immune responses have only
been observed in rare cases, usually in trials utilising the
intramuscular delivery route, such as anti-Dystrophin
T-cells in Duchenne’s Muscular Dystrophy (DMD) trials,
for example (Mendell et al., 2010). More recently, how-
ever, this effect has also been observed in organs consid-
ered to be more immune-privileged. In a clinical study
investigating mucopolysaccharidosis type IIIB, anti-
transgene T-cells were documented following intracranial
delivery of AAV5 (Tardieu et al., 2017).
Interestingly, anti-capsid T-cell responses may not nec-
essarily be deleterious for AAV-mediated gene therapy
strategies. Initiation of tolerance to AAV capsids in two
clinical studies has been observed which appeared to be
mediated by the induction of regulatory T-cell (Treg)
responses in which signalling via the programmed cell
death protein-1 (PD1) and its cognate ligand PDL-1 was
implicated (Mueller et al., 2013; Ferreira et al., 2014). In
these trials, patients received AAV1 intramuscular injec-
tions which apparently led to the infiltration of Treg cells
in situ. The capacity of Treg cells to attenuate immune
responses, for example by inhibiting CD8+ cytotoxic T-
cells (via induction of apoptosis via granzyme- and
perforin-dependent pathways) and secretion of regulatory
cytokines (e.g. interleukin-10 or interleukin-35), suggests
that therapeutic augmentation of Treg responses may be
beneficial for in vivo gene therapy (Gernoux, Wilson &
Mueller, 2017).
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IV. HUMORAL IMMUNE RESPONSES TO AAV
There is a clear role for the innate and cellular arms of the
immune system in limiting the efficacy of AAV-based gene
transfer strategies. It is now well established that the genera-
tion of antibodies against various viral components also rep-
resents a significant barrier for AAV gene therapy. This
section will review the role of the humoral immune response
in terms of pre-existing humoral immunity and the induction
of anti-vector antibody responses. Understanding the funda-
mental biological concepts underpinning the production of
antibodies and the mechanisms of neutralising antibodies is
key to deriving counterstrategies.
(1) How are antibodies produced?
Antibodies are glycosylated proteins that can be presented on
the surface of B-cells [and act as antigen receptors (B-cell
receptors)] or secreted by B-cells to bind to and neutralise
target proteins. Antibodies are composed of two ‘light’ and
two ‘heavy’ chains which are linked by disulphide bonds.
At the N-terminus on an antibody are the hypervariable
regions which determine antigen specificity. Five classes of
antibodies have been described (IgM, IgD, IgG, IgA, IgE),
each varying according to their respective C-terminal
domains, termed Fc regions. Fc regions mediate the effector
functions of antibodies, for instance when facilitating
antibody-dependent cell-mediated cytotoxicity by recruiting
CD8+ T-cells (Hoffman, Lakkis & Chalasani, 2016).
Immature B-cells originate from the bone marrow in adult
humans. They differentiate from haematopoeitic stem cells
into pro-B-cells, then pre-B-cells and then immature B-cells.
This development follows rearrangement of immunoglobu-
lin heavy and light chains on the cell surface, resulting in
expression of an antigen-specific IgM B-cell receptor
(Thomas, Srivastava & Allman, 2006). Immature B-cells
migrate to the spleen and lymphoid organs where they
undergo activation via antigen recognition by the B-cell
receptor and helper signals from CD4+ T-cells. Antigen
binding to B-cell receptors activates gene expression changes
and internalisation of the antigen into an endosome. Antigen
proteins are subsequently degraded and presented on the B-
cell surface by MHC class II molecules, which facilitates
interactions with helper CD4+ T-cells (Victora &
Nussenzweig, 2012). Some activated B-cells develop into
plasmablasts without entering the B-cell follicles within the
spleen. Others return to the follicles where they undergo
affinity maturation of antigen-binding sites [via somatic
hypermutation (SHM)] and immunoglobulin class switching
[via class-switch recombination (CSR)] to generate high-
affinity antibody-producing plasma cells and memory B-cells
with a diverse set of effector functions. Here, SHM induces
point mutations in antigen-binding regions to enable selec-
tion of high-affinity clones whilst CSR replaces DNA
sequences that dictate isotype classes. The latter permits the
generation of antibodies with various effector functions with-
out altering their antigenic specificity. These plasma cells
home to the bone marrow and produce antibodies indepen-
dently of further antigen exposure (Muramatsu et al., 2000;
Chaudhuri & Alt, 2004; Shlomchik & Weisel, 2012).
(2) How do antibodies neutralise AAV?
Despite the relevance of pre-existing and induced humoral
immunity against AAV, the precise mechanisms by which
antibodies neutralise AAV have yet to be elucidated. Here
we will summarise the main mechanisms that antibodies uti-
lise to neutralise viral infections.
Antibodies can have a neutralising or binding (non-neutra-
lising) function. A neutralising antibody (NAb) is defined as
one that is capable of inhibiting the infectivity or pathogene-
sis of a virus. Binding, or non-neutralising antibodies, are
thought to lack neutralising activity but may be involved in
the recruitment of immune cells and the induction of
antibody-dependent cellular cytotoxicity (ADCC)
(Schmaljohn, 2013). ADCC involves the binding of anti-
bodies to a target cell (for instance, one that is virally infected)
which in turn initiates the lysis of that cell by an effector cell
(Hashimoto, Wright & Karzon, 1983). This process can be
mediated by NK cells, for example, which recognise the Fc
portion of an antibody via cell-surface expression of Fcγ
receptors such as CD16 (Chen et al., 2018). A comparable
process is antibody-dependent cellular phagocytosis
(ADCP), in which viral particles, or virally infected cells,
are bound by antibodies whose Fc portions are recognised
by Fcγ on phagocytic cells (Tay, Wiehe & Pollara, 2019).
The precise contribution of ADCC and ADCP to the clear-
ance of transduced cells following administration of AAV
requires further investigation, however.
Some NAbs can impede a virus by inhibiting its function
prior to its binding to a cell. IgA and IgM antibodies can
induce aggregation of certain types of bacteria, and some
IgG antibodies have exhibited this function in the context
of polio virus infections, for example (Brioen, Dekegel &
Boeyé, 1983). Other antibodies appear to induce loss-of-
function conformational changes in their targets that destabi-
lises their capsid structures. This has been demonstrated with
NAb against Sinbis virus (Hernandez, Paredes &
Brown, 2008) and human immunodeficiency virus-1 (HIV-
1) (Klasse & Sattentau, 2002).
NAbs can also interfere with the attachment of viruses to
cells. For example, NAbs can bind to HIV-1 gp120 and
thereby prevent the binding of the virus to its cognate recep-
tor, CD4 (Klasse et al., 2012). This mechanism, thought to
occur due to steric interference between virus cell-binding
ligands and cell surface receptors, has also been shown to
apply to flavivirus (He et al., 1995), parvovirus (Booy
et al., 1998) and rotavirus (Ruggeri & Greenberg, 1991).
Other NAbs may interfere with enveloped viruses like
HIV-1 post-attachment by preventing fusion of viral and
endosomal membranes once the virus enters its target cell
(de Rosny et al., 2004). Non-enveloped viruses enter cells via
endocytosis and must ‘escape’ from endosomes in order to
prevent their degradation in lysosomes. Antibodies against
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polio virus have been shown to destabilise capsid proteins so
that the virus cannot escape from the endosome (Wien
et al., 1995).
NAbs may also interfere with other essential viral intracel-
lular processes. For instance, some NAbs against human pap-
illoma virus have been shown to prevent trafficking of viral
DNA to the nucleus (Ishii et al., 2010). Recently, a novel
mechanism of intracellular virus neutralisation was described
in which a cytosolic antibody receptor, called Trim21, binds
to antibody-coated adenoviruses and facilitates their protea-
somal degradation (Mallery et al., 2010).
Clearly, NAbs can utilise a number of mechanisms to neu-
tralise virus infections. However, our understanding of how
NAbs interact with AAV is very limited, and only a few stud-
ies have investigated this aspect of gene therapy. A correla-
tion between the levels of NAbs and IgG titres has been
established (Kruzik et al., 2019), and it appears that IgG1,
IgG2, and IgM are the main subtypes that are correlated
with anti-AAV NAbs (a similar correlation was not observed
with IgG3 and IgG4 in this report) (Murphy et al., 2009).
However, it has not yet been characterised which subtype is
primarily responsible for neutralising activity against AAV
as opposed to binding activity against AAV. One study
showed that NAbs are associated with the accumulation of
AAV in the lymphoid organs, whilst binding antibodies have
been shown to increase transduction of the liver, highlighting
the possibility that certain subclasses of antibody may be
capable of partially redirecting vector tropism (Fitzpatrick
et al., 2018). Further, interactions between humoral immune
responses and complement pathways have also been identi-
fied. In an in vivo study, mouse models deficient in comple-
ment receptor 1/2 and complement component
3 demonstrated a delayed antibody response to AAV2 vec-
tors and significantly lower terminal NAb titres compared
to wild-type controls (Zaiss et al., 2008). Interactions between
Ig subtypes and the cellular immune system have also been
observed, with one study highlighting a possible correlation
between IgG3 antibody levels and the development of T-cell
reactivity against AAV capsid proteins (Mingozzi et al., 2009).
(3) Pre-existing humoral immunity
The prevalence of patient seropositivity (the harbouring of
antibodies against an antigen) varies substantially depending
upon the particular serotype in question and the geography
in which the study was conducted (Calcedo et al., 2009; Bou-
tin et al., 2010). In studies examining people from four conti-
nents, the prevalence of NAbs against AAV1/2 ranged from
30 to 60%, which was greater than the 15–30% range
observed for AAV7/8/9, and 2% seropositivity for AAV4
(Calcedo et al., 2009). These disparities may reflect the likeli-
hood of wild-type infections by a particular serotype, given
that pre-existing humoral immunity, much like pre-existing
cellular immunity described above, is thought to arise from
asymptomatic wild-type AAV infections throughout a
patient’s lifetime. Anti-AAV NAbs are also known to be
highly cross-reactive, and patients are often observed to
harbour NAbs against most, if not all, AAV serotypes; a find-
ing that may reflect the conservation of epitopes across differ-
ent AAV serotypes (Calcedo & Wilson, 2013).
In most liver gene transfer studies, AAV serotypes 2 and
8 have been utilised, however, in a recent clinical trial inves-
tigating haemophilia B, AAV5 was used. Of the 10 partici-
pants included in the trial, none were deemed to have
pre-existing NAbs against AAV5, and although some did
demonstrate anti-AAV5 IgG and IgM, this had no detectable
impact on the efficiency of gene transfer (Miesbach
et al., 2018). These findings have been corroborated by
reports from Drygalski et al. (2019) who used a highly sensi-
tive luciferase-based NAb assay to identify low anti-AAV5
NAb titres in haemophilia B patients undergoing gene
therapy-based FIX replacement. They also showed that
these low levels of NAbs had no observable effect on the out-
come of gene transfer in these patients. In this way, they were
able to identify a new opportunity to include anti-AAV5
NAb seropositive patients in the clinical trial who were previ-
ously ineligible (Drygalski et al., 2019).
An alternative route of administration for gene therapy-
based treatment of haemophilia B involves the injection of
AAV vectors into the muscle. In 2003, rAAV vectors were
used to deliver a functional copy of the FIX gene into male
participants with severe haemophilia B. No evidence of
local or systemic toxicity to the vector was observed up to
40 months post-injection, and the presence of antibodies
directed against FIX protein were also not detected. In
contrast to liver gene transfer studies that would be con-
ducted in subsequent years, the presence of anti-AAV
NAbs in these patients did not have an apparent impact
on the efficiency of gene transfer to the muscle (Manno
et al., 2003).
Another study investigated the possibility of utilising
intrathecal injections as a treatment for mucopolysac-
charidosis type III. The prevalence of NAbs against
AAV2 and AAV9 was assessed in the sera and cerebrospi-
nal fluid (CSF) of healthy volunteers and enrolled
patients. In the sera, anti-AAV2 NAbs were detected at
a higher level than anti-AAV9 NAbs, and overall levels
of both anti-AAV2 and -AAV9 NAbs were higher in the
sera than in the CSF. Upon vector administration via
intrathecal delivery (which involves injection of a
vector-containing solution into the spinal canal such that
it reaches the CSF), the presence of these pre-existing
NAbs did impact the efficiency of gene transfer, but did
not completely block transduction (Haurigot
et al., 2013). In a non-human primate study, the detection
of pre-existing NAbs at a 1:128 titre did not have any
apparent effect on the efficacy of gene transfer when an
AAV9.GFP gene therapy was used (Gray et al., 2013).
Taken together, these findings highlight the immune-
privileged status of the CNS and demonstrate a role for
the BBB in limiting the transfer of NAbs from the sys-
temic circulation into the CSF.
Studies utilising non-human primate models have demon-
strated that pre-existing NAbs against AAV may limit the
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efficiency of transgene expression following an intravitreal
injection (IVT). Pre-existing sera NAb titres of 1:10 or
greater were found to reduce transgene expression, although
some animals with 1:25–1:100 NAb levels still exhibited
some degree of retinal transduction (Kotterman
et al., 2015). Data emerging from clinical trials, however,
have suggested that pre-existing sera NAb titres may not rep-
resent a significant barrier to effective transduction of the ret-
ina via IVT. In one study, 2/5 patients demonstrated
improvements in visual acuity following administration of
an AAV-based treatment for LHON, in spite of the fact they
harboured sera NAb titres of 1:5120 and 1:20480 at baseline
(Feuer et al., 2016). Further, in a follow-up study to this trial,
the same investigators showed that, of the 14 patients
enrolled in the clinical study, the four that demonstrated
the greatest increases in visual acuity also had the highest
(1:20480) NAb titres at baseline (Guy et al., 2017). By con-
trast, a clinical trial investigating AAV2.sFLT1 [soluble
FMS-like tyrosine kinase-1, an anti-vascular endothelial
growth factor (VEGF) agent] IVT gene therapy for neovas-
cular age-related macular degeneration (nAMD) showed
that pre-existing NAb titres of 1:400 appeared sufficient to
preclude effective vector administration and transduction of
the retina. sFLT1 protein expression was also blocked in
patients with 1:3200 NAb titres but no evidence of vector
neutralisation was seen in the patient with a baseline titre of
1:100 (Heier et al., 2017).
In summary, the role of pre-existing NAbs in limiting the
efficiency of gene transfer appears to vary according to the
route of administration and choice of AAV serotype. Broadly,
systemic intravenous injections appear to be more susceptible
to NAbs, whilst administration to immune-privileged sites
such as the CNS may result in efficient gene transfer even in
the presence of low titres of NAbs.Whether the administration
of AAV to a patient with pre-existing NAbs may bemore risky
than a seronegative patient is an open question. However, it is
possible that the former route may involve injection to a
‘primed’ immune system which could induce a significant
immune response. By contrast, injection into seropositive indi-
viduals may simply result in rapid neutralisation of viral parti-
cles, circumventing any cellular transduction and concomitant
immune responses. Pre-screening trial participants for NAbs
using serum neutralisation assays prior to administration to
immune-privileged sites is a key factor in ensuring efficient
gene transfer, however, greater standardisation of these assays
may be required to establish threshold NAb levels at which
administration of AAV can be successful in seropositive indi-
viduals (Meliani et al., 2015).
(4) Induction of anti-AAV humoral immune
responses
Pre-existing antibodies to AAV represent a key barrier to suc-
cessful gene transfer in seropositive individuals. A related issue
is whether the administration of AAV induces a robust NAb
response that precludes re-administration of a gene therapy.
The importance of repeated gene transfer varies according
to the route of administration and target organ, however, in
our view, the ability to re-administer a gene therapy is a clini-
cally relevant consideration formost, if not all, in vivo gene ther-
apy programmes. Administration to young adults suffering
from haemophilia, for example, is faced with the problem that
the liver is a dividing tissue, leading to dilution of transgene
expression over time. Further, as discussed above, CD8+ T-
cell responses may clear transduced cells from target organs,
especially after systemic or intramuscular delivery, again lead-
ing to reduced transgene expression over time. In addition,
whilst many gene therapy programs are targeting monogenic
recessive disorders, there is an increasing interest in developing
AAV constructs for diseases exhibiting complex aetiologies. In
these diseases, multiple pathogenic pathways are involved
which may require sequential administration of different gene
therapies. There is also the possibility that an initial gene ther-
apy injection is sufficient to induce a robust NAb response but
insufficient to rescue a clinical phenotype. Lastly, it is possible
that methylation of viral promoter sequences may occur years
after AAV administration, which may lead to transgenic
silencing. In these scenarios, a repeat injection of AAV could
be used to circumvent reduced therapeutic transgene expres-
sion and maximise clinical benefit. Therefore, a discussion of
the possibility of NAb induction and possible strategies to cir-
cumvent these responses is warranted. In this section, we will
briefly summarise NAb responses following administration of
AAV to the liver, skeletal muscle and CNS. We then provide
a detailed analysis of NAb induction observed in ocular gene
therapy trials.
(a) Gene therapy trials targeting the liver and skeletal muscle
A number of clinical studies have reported increased anti-
AAV NAb levels after vector administration to target the
liver and skeletal muscle. In summary, these reports suggest
that these two routes of administration lead to elevated
NAb titres, which, in some cases, were observed up to
52 weeks after vector infusion. Further, the utilisation of
immunosuppression in two of the trials discussed below did
not appear to be sufficient to abrogate anti-capsid NAb
responses. Given the role that pre-existing NAbs may play
in limiting the effectiveness of gene transfer, we suggest the
induction of NAbs in these trials may represent a possible
barrier to vector re-administration in these individuals,
which may limit the clinical utility of gene therapy. A sum-
mary of humoral immune responses in clinical trials targeting
the liver and skeletal muscle for human gene therapy is pro-
vided in Table 1.
(b) Gene therapy trials targeting the central nervous system
Unlike studies investigating liver and skeletal muscle gene
therapies, clinical trials administering AAV to the CNS have
not reported the induction of NAbs. However, the results of
non-human primate and dog studies investigating the induc-
tion of NAbs following delivery to the CNS indicate possible
differences to other modes of administration. Principally,
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pre-existing sera NAb titres appear to have less impact in
neutralising vector administration, likely due to the imper-
meability of the BBB, however AAV injection to the CNS
may still result in increased NAb titres.
Gene delivery to the CNS can be achieved via systemic
vector delivery provided an appropriate AAV serotype
(Vandenberghe, 2019) [or mutated AAV capsid (Hordeaux
et al., 2018; Hudry et al., 2018)] is used. As outlined above,
the potential of gene transfer for treating diseases affecting
the CNS has been demonstrated in the context of SMA,
and an FDA-approved therapy (Zolgensma) now exists for
the condition which uses AAV9 expressing survival motor
neuron-1 (SMN-1). The earliest clinical trials investigating
SMA gene therapy via systemic delivery did not report the
induction of antibodies against either the AAV9 capsid pro-
tein or the SMN-1 transgene (Mendell et al., 2017; Al-Zaidy
et al., 2019; Lowes et al., 2019). Similarly, a study conducted
in non-human primates and piglets did not report the devel-
opment of humoral immune responses against capsid pro-
teins or transgene products, in spite of the observation of
severe toxicity following high-dose intravenous administra-
tion of an AAV9 variant, AAVhu68, carrying the SMN-1
transgene (Hinderer et al., 2018).
An alternative route of delivery to the CNS is intrathe-
cal delivery. A study investigating intrathecal delivery of
AAV9 as a possible treatment for mucopolysaccharidosis
type III showed that vector administration induced a
robust systemic humoral immune response against AAV9
capsids, despite all dogs demonstrating undetectable levels
of anti-AAV9 NAbs at baseline. Eight days after vector
administration, NAb titres were greater than 1:1000.
Interesting correlations between systemic and correspond-
ing CSF NAb titres were also observed and appeared to be
dependent upon the presence of inflammation in the CSF.
In the absence of inflammation, CSF samples were nega-
tive or had NAb titres of <1:10, however, in dogs exhibit-
ing signs of inflammation in the CNS, NAb titres of 1:100–
1:1000 were seen, suggesting that the presence of
inflammation may compromise the integrity of the BBB
(Haurigot et al., 2013).
Injections can also be performed directly into the brain in
order to transfer genes to the CNS. One non-human primate
study examined injections of AAV9 expressing acid sphingo-
myelinase (ASM) into the cerebromedullary (CM) space of a
Niemann-Pick disease type A model (a lysosomal storage dis-
ease). Slight increases in anti-AAV9 NAb levels were seen in
both the sera (1:400–1:800) and CSF (1:100–1:200) at 1 and
3 month timepoints respectively, in response to vector
administration (Samaranch et al., 2019).
(c) Gene therapy trials targeting the eye
The eye has been at the forefront of gene therapy research for
a number of reasons. First, its compartmentalised nature and
tightly regulated transport of molecules across the blood-ret-
inal-barrier (BRB) reduces the risk of vector leaking into the
systemic circulation, thereby mitigating a significant regula-
tory/safety concern (Cunha-Vaz, Bernardes & Lobo, 2011).
Second, the eye is relatively accessible for vector administra-
tion, and several well-characterised routes of delivery, such as
IVTs and subretinal injections (SRTs) are available for oph-
thalmologists. Third, a number of non-invasive tools can be
used to assess clinical endpoints for a particular therapy, such
as electroretinography (ERG) and optical coherence tomog-
raphy (OCT). Anatomically, the eye is also smaller than
other organs, such as the brain, which obviates the need for
high vector doses to achieve robust transduction of target cell
types. Lastly, the eye is generally considered to have an
‘immune-privileged’ status and generally exhibits lower
immune responses than other organs. As mentioned, this is in
part is due to the impermeability of the BRB to humoral and
cellular arms of the immune system which has been shown to
limit access of circulating anti-capsid antibodies into the eye
(Amado et al., 2010). The phenomenon may also be accounted
for by a process called anterior chamber-associated immune
deviation (ACAID). During ACAID, immunogenic antigens
Table 1. Summary of humoral immune responses in clinical trials targeting the liver and skeletal muscle for human gene therapy




Manno et al. (2006) Haemophilia B AAV2.FIX Intravenous None 7/7
Nathwani et al. (2011) Haemophilia B scAAV2/8.FIX Intravenous None 6/6
Manno et al. (2003) Haemophilia B AAV2.FIX Intramuscular None 8/8
Brantly et al. (2006) AAT deficiency AAV2.AAT Intramuscular n/a 12/12
Brantly et al. (2009) AAT deficiency AAV1.AAT Intramuscular n/a 12/12
Flotte et al. (2011) AAT deficiency AAV1.AAT Intramuscular n/a 9/9
Stroes et al. (2008) LPL deficiency AAV2.LPL(S447X) Intramuscular None 8/8
Gaudet et al. (2013) LPL deficiency AAV2.LPL(S447X) Intramuscular CyA, MMF 14/14
Ferreira et al. (2014) LPL deficiency AAV2.LPL(S447X) Intramuscular CyA, MMF, Pred 5/5
AAV, adeno-associated virus; scAAV, self-complemetary AAV; FIX, factor 9; AAT, α1-antitrypsin; LPL (S447X), low density lipoprotein
variant harbouring single point mutation; IS, immunosuppression; CyA, cyclosporin A (T-cell inhibitor); MMF, mycophenolate mofetil
(T- and B-cell inhibitor); Pred, prednisolone (steroid immunosuppressant); NAb, neutralising antibody.
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induce a tolerogenic immune response that involves regulatory
T-cell and anti-inflammatory M2 macrophage induction,
and increases synthesis of anti-inflammatory cytokines
(Taylor, 2009; Zhou & Caspi, 2010; Keino, Horie &
Sugita, 2018; Martínez-Alcantar et al., 2019). An overview of
the clinical studies reporting NAb titres for SRT and IVT gene
therapies is provided in Table 2.
(i) Gene delivery to the outer retina by subretinal
injection. A gene therapy for LCA2 was approved by the
FDA in 2018. Efforts to develop an AAV-based gene therapy
for LCA2 have helped to improve our understanding of AAV
vector immunobiology when delivered into the subretinal
space. These studies showed that the immune-privileged sta-
tus of the eye, and the relatively non-immunogenic proper-
ties of AAV as a vector did not necessarily circumvent
immune responses to vector administration.
Initial testing of humoral immune responses in C57BL/6
mouse models showed that a significant systemic antibody
response against AAV capsid proteins could be induced by
SRT. It was also found however, that the induction of systemic
humoral immunity did not preclude vector re-administration
into the ipsilateral eye (Anand et al., 2000). The authors later
characterised a deviant immune response upon SRT of AAV
two years later, and highlighted similarities to ACAID. Here,
the generation of a population of immunosuppressive
Th2-type T-cells was reported post-SRT and they were identi-
fied as potential mediators of the immune deviation mechanism
observed (Anand et al., 2002). These data contrast with later
reports which demonstrated SRT of AAV2 did not result in a
detectable increase in NAb levels. This may reflect the
discrepancy in AAV serotypes used by the two investigators,
however (Li et al., 2008).
In 2008, the first report of AAV2.hRPE65.hRPE65 (using
an RPE65 promoter) gene delivery to the subretinal space as
therapy for LCA2 was published, however, only three
patients were included in this study. None of the enrolled
patients developed humoral immunity against AAV2 follow-
ing vector administration, and sera NAb titres were either
undetectable or <1:7 at baseline throughout the 12-month
follow-up period (Bainbridge et al., 2008).
A later report (Bainbridge et al., 2015) examined the long-
term safety of AAV2.hRPE65.hRPE65 gene therapy for
LCA2, and provided evidence that intraocular inflammation
and immune responses occurred when higher doses of vector
were used. The study also highlighted a potential humoral
immune response against AAV2. In 4/4 of patients receiving
low-dose AAV2, circulating NAb titres increased throughout
the 3-year follow-up period. In the high-dose group, four
patients showed no changes in NAb levels throughout the
study period. In the other two patients, however, vector
administration apparently induced a humoral immune
response. In both of these study participants, an asymptom-
atic episode of posterior intraocular inflammation was corre-
lated with NAb titre increases. Throughout the study
however, no anti-RPE65 transgene NAbs were detected.
Crucially, this clinical trial demonstrated that humoral
immune responses could be induced against AAV2 capsids
even when a prophylactic oral glucocorticoid immunosup-
pressive drug regimen was given to patients before and after
vector administration (Bainbridge et al., 2015).
Table 2. Summary of humoral immune responses in clinical trials utilising SRT and IVT for human gene therapy






Bainbridge et al. (2008) LCA2 AAV2.hRPE65 SRT 3 Oral prednisolone 0
Bainbridge et al. (2015) LCA2 AAV2.hRPE65 SRT 12 Oral prednisolone 6
Hauswirth et al. (2008) LCA2 AAV2.hRPE65 SRT 3 n/a 1
Jacobson et al. (2012) LCA2 AAV2.hRPE65 SRT 14 Topical steroids 6
Maguire et al. (2008) LCA2 AAV2.hRPE65v2 SRT 3 Oral prednisolone 1
Maguire et al. (2009) LCA2 AAV2.hRPE65v2 SRT 12 Oral prednisolone 2
Bennett et al. (2012) LCA2 AAV2.hRPE65v2 SRT* 3 Oral prednisolone 0
Le Meur et al. (2018) LCA2 AAV4.RPE65 SRT 9 Oral prednisolone 2
Ghazi et al. (2016) RP AAV2.hMERTK SRT 6 None 2
Rakoczy et al. (2015) nAMD AAV2.sFLT1 SRT 9 Topical steroids 2
Constable et al. (2016) nAMD AAV2.sFLT1 SRT 21 Topical steroids 3**
Wan et al. (2016) LHON AAV2.ND4 IVT 9 Oral prednisolone 0
Feuer et al. (2016) LHON AAV2.P1ND4v2 IVT 5 None 1
Guy et al. (2017) LHON AAV2.P1ND4v2 IVT 14 None 2
Bouquet et al. (2019) LHON AAV2.ND4 IVT 15 None 14
Heier et al. (2017) nAMD AAV2.sFLT1 IVT 19 None 7
AAV, adeno-associated virus; LCA2, Leber’s congenital amaurosis type II; RP, retinitis pigmentosa; nAMD, neovascular age-related mac-
ular degeneration; LHON, Leber’s hereditary optic neuropathy; RPE65, retinal pigment epithelium-65; RPE65v2, retinal pigment
epithelium-65 with enhanced Kozak sequence; MERTK, c-Mer protooncogene tyrosine kinase; sFLT1, soluble FMS-like tyrosine kinase;
ND4, NADH dehydrogenase subunit 4; P1ND4v2, NADH dehydrogenase subunit 4 containing mitochondrial targeting sequence; SRT,
subretinal injection; IVT, intravitreal injection; IS, immunosuppression; NAb, neutralising antibody.
*Participants received an SRT of AAV2 into the contralateral eye.
**In this study, 3/9 patients seroconverted after receiving IVT of AAV2 (for the remaining 12 patients, NAb titres were not reported).
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Other studies investigating SRT delivery of AAV2.CB.
hRPE65 (chicken β-actin promoter) for LCA2 gene therapy
have reported similar results. In a phase I trial, humoral
immune responses were measured at baseline, and at days
14 and 90. Whilst 2/3 patients did not demonstrate an
anti-vector NAb response, one patient exhibited a 7.5-fold
increase in their 90-day antibody titre compared to baseline
levels, however, this did not correlate with AAV2 capsid-
specific reactivity of peripheral lymphocytes in which no
changes were observed in any patients between baseline
and days 14 or 90. In this study, anti-transgene NAb induc-
tion was not reported (Hauswirth et al., 2008).
In a long-term assessment of the safety and efficacy of
AAV2.CB.hRPE65, humoral immune responses were mea-
sured throughout a three-year follow-up period. 8/14
patients enrolled in the study actually demonstrated a decline
in anti-AAV2 NAb titres throughout the study, whilst 6/14
demonstrated increases in NAb titres compared with base-
line. Across all cohorts tested, no apparent correlation
between AAV2 dosages and anti-AAV2 antibody titres was
evident (Jacobson et al., 2012). Interestingly, in the studies
of Hauswirth et al. (2008) and Jacobson et al. (2012), no
patients were given prophylactic glucocorticoid immunosup-
pressants, and this did not have an apparent effect on the
induction of humoral immunity when compared to the
patients in Bainbridge et al. (2008, 2015).
In a phase I trial published in 2008, AAV2.CB.hRPE65v2
[voretigene neparvovec (Luxturna)] SRT administration was
found to induce an anti-AAV2 NAb response in 1/3 patients
enrolled in the study. The levels of this patient’s NAbs were
elevated after 14 days, and did decrease by 30 days post-
SRT but remained high compared to baseline. No evidence
of anti-RPE65 NAbs were observed (Maguire et al., 2008).
The safety and efficacy of AAV2.CB.hRPE65v2 was then
further investigated in a phase I dose escalation trial which
introduced middle- and high-dose cohorts. In the middle-
dose cohorts, 4/6 patients did not exhibit signs of an anti-
AAV2 humoral immune response. In 2/6 patients however,
significant increases in NAb levels were evident versus baseline
values. Perhaps unexpectedly, in the high-dose cohort, no
evidence of a humoral immune response was detected in
any of the three patients. It should be noted however, that
the two patients from the middle-dose cohort who exhibited
the greatest increases in NAb levels also had the highest NAb
levels at baseline. Therefore, it is possible that these patients
had some pre-existing immunity to AAV2 that was sufficient
to induce a humoral immune response upon vector adminis-
tration but not sufficient to be excluded from the trial
(Maguire et al., 2009).
The investigators then tested whether re-administration of
AAV2.CB.hRPE65v2 resulted in increased sera NAb levels.
Of the three patients included in this follow-on trial, baseline
NAb levels were 1:1–1:3.16 and remained at these low levels
in spite of vector administration into the contralateral eye
(Bennett et al., 2012). Notably, in all studies examining
AAV2.CB.hRPE65v2, systemic corticosteroid immunosup-
pressive treatment was given to patients to mitigate the
occurrence and severity of vector-mediated immune
responses.
The majority of studies investigating gene therapy for LCA2
have utilised AAV2 for the delivery of therapeutic transgenes.
One study has utilised theAAV4 serotype, however.Of the nine
patients enrolled in this study, six did not exhibit detectable anti-
AAV4 IgG at baseline or after vector administration. In two
patients, a significant increase in anti-AAV4 IgG and NAb
levels were seen. In one patient, a NAb titre of 1:50 was seen
at baseline, but remained unchanged at 1:50 until 180 days
follow-up, indicating that a humoral immune response was
not induced by AAV4 SRT. In this study, prednisolone gluco-
corticoids were administered daily 1 week before and after the
SRT of AAV4 prophylactically to inhibit immune reactions to
the vector (Le Meur et al., 2018).
Outside of LCA2, SRT of AAV vectors has been investi-
gated for possible therapeutic effects in other genetic eye dis-
orders like retinitis pigmentosa. More recently, the platform
has also been applied to diseases with complex etiologies
like nAMD.
Mutations in MER proto-oncogene tyrosine kinase
(MERTK) cause retinitis pigmentosa. MERTK aberrations
disrupt phagocytic activity of RPE cells, which in turn causes
degeneration of rod and cone photoreceptors. AAV2 has
been used to deliver functionalMERTK genes into RPE cells
via SRT. In a phase I study, 3/6 patients demonstrated
improvements in visual acuity and all patients exhibited
acceptable safety profiles. In 2/6 patients, anti-AAV2
humoral immune responses were also recorded and 10–
26-fold increases in NAb titres were observed. However, no
data were reported for these patients’ NAb titres after one
year of follow-up (Ghazi et al., 2016).
The first reports of SRT gene therapy being used to
treat nAMD in patients were published in 2015. In this
phase I study, nine patients were enrolled and adminis-
tered rAAV2.sFLT1 via SRT. The therapy was shown to
reduce the requirement for ‘rescue’ injections of intravi-
treal anti-VEGF agents (Ranibizumab), whilst no drug-
related adverse events were reported. Total anti-AAV2
and neutralising AAV2 antibodies were reported
between baseline and one-year follow-up in six of the
patients enrolled. In 4/6 patients, NAb titres remained
unchanged at <1:20 throughout the study. In two
patients, however, a robust humoral immune response
was evident, these subject’s NAb titres were <1:20 at
baseline and increased to 1:20–1:100 at the 3-week time-
point (Rakoczy et al., 2015).
Further testing of this gene therapy in a phase IIa study
corroborated previous findings. Of the 21 patients studied,
nine displayed no anti-AAV2 NAbs at baseline, whilst
12 had titres between 1:20 and 1:100. In 3/9 patients with
no detectable NAbs at baseline, anti-AAV2 NAbs were
observed at completion of the study. In this publication how-
ever, data on NAb levels were not included, rendering fur-
ther analysis challenging (Constable et al., 2016).
(ii) Gene delivery to the inner retina by intravitreal
injection. Compared to SRT, IVT is a much simpler route
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of delivery for AAV-based gene therapies. IVTs can be per-
formed in an ophthalmologist’s office in a matter of minutes,
and only requires topical analgesics for the injection. IVTs
are also necessary to target inner retinal cells, principally
RGCs. Recently, evidence has emerged suggesting that spe-
cific AAV serotypes can target the outer retina/photorecep-
tor layer via IVT. This has increased interest in this delivery
route for treating common blinding disorders like nAMD
and diabetic retinopathy (Dalkara et al., 2013; Grishanin
et al., 2019). A number of preclinical and clinical studies uti-
lising IVTs of AAV gene therapies have now been com-
pleted. These have highlighted similarities and differences
between IVT and SRT in terms of the induction of humoral
immunity against AAV capsid proteins.
One of the earliest reports contrasting the induction of
NAbs following SRT and IVT of AAV2 was published in
2008 (Li et al., 2008). In a rodent model, it was shown that
unilateral SRT did not trigger a humoral immune response
against AAV2 capsid proteins. As a result, subsequent
administration of AAV2 into the contralateral eye was per-
missible when delivered by SRT and IVT, a finding that sup-
ported clinical studies investigating SRTs and contralateral
eye administration (Bennett et al., 2012). When an initial
injection of AAV2 was delivered via IVT however, the induc-
tion of humoral immunity was evident. The authors reported
up to tenfold increases in total anti-AAV2 antibodies follow-
ing IVT, a finding that correlated with the levels of NAbs
against AAV2 capsids. Upon re-administration of AAV2 to
the contralateral eye, the authors found that SRT delivery
resulted in robust transduction of the outer retina, however,
they observed diminished expression if the IVT delivery
route was used for vector re-administration (Li et al., 2008).
Their findings therefore highlighted possible differences
between the immune mechanisms employed by the vitreous
cavity versus the subretinal space, however, it should be noted
that their observation that SRT did not result in a humoral
immune response is in partial disagreement with some clini-
cal (Hauswirth et al., 2008; Jacobson et al., 2012; Bainbridge
et al., 2015) and preclinical studies (Anand et al., 2000, 2002).
In non-human primate studies, further evidence has arisen
that IVT may induce stronger NAb responses than SRT.
Kotterman et al. (2015) published data relating to the induc-
tion of anti-AAV NAbs following IVT of multiple serotypes
and mutagenised capsid protein AAV variants, and their
analysis showed that IVT of all AAV variants caused a
NAb response. They tested AAV2, AAV5, AAV9, AAV7m8
(peptide-insert mutant AAV) and AAV2 (Y-F tyrosine
mutant AAV2), all of which were found to elevate NAb levels
from 1:1–1:100 at baseline to 1:100–10000 after the injec-
tion. In some of the non-human primates, NAb levels were
assessed over a period of 7 months. All injected animals dem-
onstrated consistent NAb levels in the first 3 months follow-
ing IVT, but some showed a 2–5-fold decline after
3 months. In general however, the persistence of elevated
NAb titres for long periods after gene therapy administration
was observed. The authors also reported cross-reactivity of
NAbs generated against multiple AAV serotypes. Here,
injection of AAV5 and AAV9 was found to increase anti-
AAV2 NAb levels, and IVTs of AAV2, AAV7m8 and
AAV2(Y-F) induced anti-AAV5, -AAV8 or -AAV9 humoral
immune responses. The authors also noted an interesting but
non-significant trend in which higher pre-injection NAb
titres correlated with a smaller change between pre- and
post-injection titres. It was postulated that this may be due
to higher rates of vector neutralisation which attenuated ret-
inal transduction and antigen presentation to the immune
system (Kotterman et al., 2015).
In a comparable non-human primate study, IVT and
SRT of AAV capsid mutant variants AAV7m8 and
AAV8BP2 (9mer peptide insert into AAV8 capsid) were
found to induce humoral immune responses. Following
IVT, AAV8BP2 and AAV7m8 increased sera NAb titres in
non-human primate models post-IVT. These increases
appeared to be slightly lower than that observed by Kotter-
man et al. (2015), however, this discrepancy may be explained
by a multitude of confounding variables, such the different
timepoints used in the study, difficulties in accurately titering
AAV preparations (rendering comparison between studies
challenging) and of course the use of different AAV sero-
types/mutant capsids. This study also compared sera NAb
titres to vitreous NAb titres. After IVT of AAV8BP2, post-
injection vitreous NAb titres remained unchanged at
<1:3.16 in all animals. Following AAV7m8 IVT however,
vitreous NAb levels rose in 2/6 non-human primates. Inter-
estingly, this study also reported increases in NAb levels fol-
lowing SRT in some animals (1/3 after AAV8BP2 SRT
and 4/4 after AAV7m8 SRT), a finding that reflects certain
preclinical and clinical results (Anand et al., 2000, 2002;
Hauswirth et al., 2008; Jacobson et al., 2012; Bainbridge
et al., 2015) but disagrees with the results of investigations uti-
lising mouse models (Li et al., 2008).
Reports detailing the induction of humoral immunity in
clinical trials following IVT of AAV-based gene therapies
arose sometime after those utilising the SRT route of admin-
istration. In 2016, one study described the use of AAV2
expressing mitochondrial reduced nicotinamide adenine
dinucleotide (NADH) dehydrogenase subunit 4 (ND4) as a
possible treatment for LHON. Patients enrolled in this clini-
cal trial were given oral prednisolone for 1 week prior to and
8 weeks after the administration of the therapy. At baseline
and 6 months post-IVT, NAb titres in all nine patients
remained unchanged and at levels below 1:20, however, it
should be noted that no improvements in visual acuity were
observed in this study (Wan et al., 2016).
In the same year, data from another clinical trial investi-
gating LHON gene therapy were published. In this study
however, a self-complementary AAV2 (scAAV2; contains
dsDNA genome) harbouring tyrosine to phenylalanine sub-
stitutions and an ND4 gene expression cassette (AAV2.
CBA.P1ND4v2) was utilised, and no immunosuppressants
were given to the five patients. Only one patient experienced
an increase in NAb levels after 7 days, which then decreased
back to baseline levels after 90 days follow-up. It should be
noted however, that the other four patients enrolled
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exhibited very high (1:5120–1:20480) NAb levels at baseline,
but this did not appear to inhibit transduction efficiency/
therapeutic efficacy (Feuer et al., 2016). In a follow-up to
these initial results, similar data were reported that corrobo-
rated the previous findings (Guy et al., 2017). In accordance
with other studies investigating SRT of AAV gene therapies
(Hauswirth et al., 2008; Jacobson et al., 2012; Bainbridge
et al., 2015), there was no obvious correlation between base-
line NAb titres and the induction of a humoral antibody
response. Another comparison between this study and data
from SRT investigations is that the observation of a signifi-
cant humoral immune response correlated with an episode
of anterior uveitis, a finding similar to that reported by Bain-
bridge et al. (2015).
Induction of humoral immune responses in a subset of
patients administered with AAV2 gene therapies in the
absence of prophylactic immunosuppressants has also been
shown in a phase I/II study investigating the use of AAV2.
ND4 in LHON patients. In this trial, 13/15 patients exhib-
ited episodes of anterior uveitis and vitritis, two of which
were administered immunosuppressants to counteract this
ocular inflammation. The authors also concluded that there
was no observable correlation between the ocular inflam-
mation score (OIS) and the vector dose administered. They
also reported no apparent association between the humoral
immune response and vector dose, nor the humoral
immune response and OISs. Most patients did demonstrate
an increase in their NAb titres after AAV2 IVT, however.
3/3 patients receiving the lowest dose (9E9 vector
genomes/eye) and 3/3 patients receiving 3E10 vector
genomes/eye showed increases in NAb titre levels from
baseline which largely persisted throughout the 96-week
follow-up period. In patients who received 9E10 viral
genomes/eye, however, the results were less clear, and
whilst a transient increase in NAb titres was observed in
5/6 patients, these resolved back to baseline levels in two
cases, but persisted until week 96 in the remaining three
cases. Finally, in patients who received 1.8E11 viral
genomes/eye, 3/3 showed elevated NAb titres shortly after
receiving an IVT of AAV2.ND4. Overall, this study pro-
vided evidence that AAV2 IVTs may induce NAb
responses, however, it should be emphasised that these
patients did not receive prophylactic immunosuppressant
therapy (Bouquet et al., 2019). Here, more research is
required to understand whether glucocorticoid therapy is
able to circumvent the induction of humoral immunity in
patients receiving IVTs of AAV2 and what the importance
of this finding may be, for instance, in enabling re-
administration of the vector to the ipsilateral or
contralateral eye.
Whilst clinical studies utilising AAV2 IVT have mostly tar-
geted genetic diseases, the approach has also been used to
target nAMD. AAV2.sFLT1 (delivered by IVT) was studied
in 19 patients, and 6/19 demonstrated substantial reductions
in retinal oedema and improvements in vision. There was
some evidence of the induction of humoral immunity against
AAV2, however, this was not associated with the vector dose
administered. 6/6 patients in the low-dose groups (2E8-2E9
vector genomes/eye) showed no detectable increase in NAb
levels. In patients who received 6E9 vector genomes/eye,
2/3 demonstrated anti-AAV2 NAb responses. For patients
in the first 2E10 cohort, 3/3 exhibited increased NAb titres
throughout the one-year investigation period. In the other
cohort of patients receiving the highest dose of AAV2.sFLT1
(2E10 vector genomes/eye) 2/7 demonstrated increases in
NAb titres. The utilisation of prophylactic immunosuppres-
sants was not reported in this study, however, topical steroids
were used to treat episodes of pyrexia and intraocular inflam-
mation in two patients in the high-dose cohort (Heier
et al., 2017).
(iii) Is the eye immune-privileged with respect to AAV gene
therapies?. Despite the assumption that the eye is a rela-
tively immune-privileged environment and therefore favour-
able for testing gene therapies, the above discussion
highlights a number of key findings suggesting that humoral
immunity to AAV, either pre-existing via wild-type infection
or induced by vector administration, may represent a signif-
icant hurdle for successful gene transfer to the inner and
outer retina. The number of patients enrolled in the clinical
trials described above is limited, reflecting the small patient
populations for their respective indications. However, in
our view, a number of trends may be evident in the data.
These patterns highlight unanswered questions in the field
and identify possible research questions for the future. A
summary of a possible role of humoral immunity in response
to ocular gene therapies is summarised in Fig. 1.
(1) Only a subset of patients demonstrate increases in anti-
AAV NAb levels after vector administration via SRT
(Bainbridge et al., 2015; Constable et al., 2016) or
IVT (Heier et al., 2017; Bouquet et al., 2019). Some
of these patients exhibit very low/undetectable NAb
titres at baseline, others had high NAb titres, yet evi-
dence of the induction of humoral immunity to AAV
was occasionally observed in both cases post-injection.
One possible explanation is that patients that are sero-
negative at baseline may harbour AAV reactive T-cells
(Mingozzi et al., 2007; Veron et al., 2012) which facili-
tate a strong humoral immune response upon vector
administration.
(2) One trend is that the significant increases in NAb
levels observed in some patients appear to correlate
with episodes of intraocular inflammation. A num-
ber of studies investigating SRT (Bainbridge
et al., 2015) and IVT (Guy et al., 2017; Heier
et al., 2017; Bouquet et al., 2019) have shown that
the onset of events such as vitritis and anterior uve-
itis was seen in patients who exhibited the greatest
changes in their NAb titres between baseline and
the weeks/months following vector administration.
It should also be noted that some of the patients
who developed intraocular inflammation had very
low/undetectable NAbs at baseline. More research
is required to understand why this subset of patients
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developed much stronger NAb responses compared
to other participants. Further, patients who devel-
oped high NAb titres and intraocular inflammation
may be at increased risk of CD8+ T-cell infiltration
into the retina and the clearance of transduced cells
over time, which may eventually lead to the loss of
therapeutic efficacy. We suggest that patients who
develop intraocular inflammation are closely moni-
tored for signs of diminished transgene expression.
In this regard, considering the apparent failure of
AAV reactive T-cells to recirculate in peripheral
blood (Vandamme et al., 2017) (rendering their
ex vivo analysis via blood sampling/ELISPOT assay
challenging), episodes of intraocular inflammation
could serve as a surrogate biomarker for patients
most at risk of deleterious CD8+ T-cell infiltration
into the retina.
(3) There is no apparent correlation between baseline
NAb titres and the magnitude of increase in NAb titre
observed after vector administration. Of the patients
that did exhibit significant increases in NAb levels after
SRT (Bainbridge et al., 2015; Rakoczy et al., 2015;
Constable et al., 2016) and IVT (Guy et al., 2017;
Heier et al., 2017; Bouquet et al., 2019), high and
Fig 1. The humoral immune response in relation to ocular gene therapy. Our review suggests that a subset of patients develop anti-
AAV NAbs after SRT or IVT of AAV, however, it is not clear whether this can be circumvented via administration of perioperative
systemic steroids. Further studies are needed to determine whether the induction of anti-AAVNAbs affects re-administration into the
eye by IVT/SRT or into other organs. In addition, the precise mechanisms utilised by AAV NAbs remain unknown, and more
research is needed to elucidate the basis of their neutralising activity. AAV, adeno-associated virus; APC, antigen presenting cell;
BP, bipolar cell; CSR, class switch recombination; GCL, ganglion cell layer; IVT, intravitreal injection; MHC, major
histocompatibility complex; NAb, neutralising antibody; PC, plasma cell; PR, photoreceptor; RPE, retinal pigment epithelium;
SHM, somatic hypermutation; SRT, subretinal injection.
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low/undetectable baseline NAb titres were observed.
This evidence may discount a possible theory that high
baselineNAb levels lead to rapid neutralisation of vectors
upon injection, which in turn precludes the presentation
of their capsid proteins to the immune system
(Kotterman et al., 2015). It also suggests that a ‘primed’
immune system (i.e. one harbouring NAbs/B-cell epi-
topes against AAV) may not necessarily lead to stronger
NAb responses compared to a patient who has no detect-
able NAbs at baseline.
(4) It is unclear whether AAV administration via SRT or
IVT induces NAb responses in a dose-dependent man-
ner, whichmay simply reflect the small sample sizes used
in these studies. However, it is notable that two studies
(Maguire et al., 2009; Bennett et al., 2012) investigating
SRT of AAV2 found no evidence of a dose–response
effect. Further, in studies using IVT for vector delivery,
one reported higher frequencies of elevated NAb titres
in the low-dose group than the medium-dose group
(Guy et al., 2017), and another detected NAb responses
in both low- and high-dose groups (Bouquet
et al., 2019). In the largest study reported in the literature,
no NAb response was reported in the low-dose group,
but equivalent increases in NAb levels were seen in the
medium- and high-dose groups (Heier et al., 2017).
One possible explanation is that delivery of AAV above
a certain threshold is sufficient to induce NAb produc-
tion, but this might not be further enhanced by adminis-
tration of additional capsid antigens.
(5) The administration of perioperative steroids may not be
sufficient to attenuate production of anti-AAV NAbs.
Of the 16 clinical studies highlighted herein, seven
reported the use of oral prednisolone glucocorticoid ste-
roids prophylactically to treat the immunological com-
plications of AAV gene transfer. Of these seven
however, four reported increased NAb levels in some
of the patients enrolled, suggesting that steroid therapy
may not have been sufficient in circumventing humoral
immunity in these individuals (Maguire et al., 2008,
2009; Bainbridge et al., 2015; Le Meur et al., 2018).
(6) Further research is required to understand how the
induction of anti-AAV NAbs may affect vector re-
administration in ocular gene therapy trials, especially
for the IVT route of delivery. Some of the studies dis-
cussed showed that high NAb titres can persist for
years after delivery of AAV via SRT and IVT in a sub-
set of patients (Jacobson et al., 2012; Bainbridge
et al., 2015; Heier et al., 2017; Bouquet et al., 2019),
and whilst most studies suggest that high pre-existing
sera NAb levels limit the efficiency of gene transfer to
the retina (Kotterman et al., 2015; Heier et al., 2017),
others showed that patients with high NAb titres at
baseline actually demonstrated the greatest therapeu-
tic response to the gene therapy (Guy et al., 2017). In
this regard, one possible line of investigation could be
to determine the effect that IVT or SRT AAV admin-
istration has on vector re-administration via other
routes, e.g. intravenous infusion for liver indications.
In the future, this may be pertinent to patients who
exhibit multiple morbidities affecting different organs
and require several gene therapy treatments.
V. POSSIBLE STRATEGIES TO CIRCUMVENT
HUMORAL IMMUNITY TO AAV
As discussed above, an increasing body of evidence impli-
cates a deleterious role for pre-existing and induced NAbs
in the context of retinal gene therapy. Further, it is unclear
whether oral prednisolone is effective at inhibiting NAb
responses. This suggests that the development of strategies
to circumvent humoral immunity to AAV will likely be help-
ful in improving the outcomes of ocular gene therapy trials.
In this section we review a number of possible strategies that
may be applicable to this problem.
(1) Overcoming pre-existing AAV NAbs
As outlined above, pre-existing NAbs against AAV represent
a major hurdle to the successful application of gene transfer
technologies, and may even have a detrimental effect in
immune-privileged sites like the CNS and retina. To over-
come this problem, a number of approaches have been
reported, including modifications to the vectors and the clin-
ical procedures. These are summarised in Table 3.
(a) Altering the route of administration
This strategy may be applied to some gene therapies target-
ing certain organs/tissues. For instance, we have discussed
how intramuscular (Manno et al., 2003) and intravenous
(Miesbach et al., 2018) injections of AAV can be used to treat
haemophilia B. Data from one study would suggest that
injections into the muscle are less susceptible to the presence
of pre-existing NAbs than intravenous infusions, highlighting
a possible strategy to administer AAV to haemophilia B
patients who would normally be excluded from clinical trials
(Manno et al., 2003). Similarly, intrathecal delivery of AAV to
the CSF has been shown partially to circumvent pre-existing
anti-AAV9NAbs (Haurigot et al., 2013), suggesting this mode
of administration may be preferable to systemic administra-
tion of AAV9 for delivering genes to the CNS (Jackson, Day-
ton &Klein, 2015). However, it should be noted that altering
the route of administration may attenuate effective transduc-
tion and therapeutic efficacy in a target organ.
(b) Use of alternative AAV vectors
In spite of the high rates of cross-reactivity exhibited by anti-
AAVNAbs (Boutin et al., 2010), alternative AAV vectors with
differing epitopes might be able to evade pre-existing or
induced humoral immunity. This may involve the utilisation
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Table 3. Summary of possible strategies to overcome pre-existing NAbs against AAV
Strategy Advantages Disadvantages Translational barriers




May alter the pattern of
transduction, reducing gene
delivery to target cell type or tissue.
Limited number of routes of
administration depending on the
target tissue
Low: possible to draw on
examples from other clinical
trials demonstrating safe vector




Increasing number of novel
AAV vectors identified which
may be effective at NAb
evasion. Increasing
understanding of AAV
epitopes is enabling rational
mutation of antigenic regions
could be applied to any
vector. In vitro and in vivo
screens available to identify
resistant vectors
Engineering novel AAVs can
expensive and technically
challenging, especially when
applying multiple rounds of in vivo
selection. Novel AAVs may be able
to circumvent NAbs but may have
unwanted and unintended
properties such as high toxicity
High: extensive safety and efficacy
testing likely required by
regulators to demonstrate
benefits of novel capsid in
preclinical models and patients.
High economic cost associated







Data suggest limited resistance of
PEGylated AAV to NAbs. Limited
number of examples of other
biological polymers applied to
AAV to date
High: safety of biological
polymers may be established,
but extensive safety testing
would be required for novel
formulated vectors
Use decoy capsids Clinically translatable if
‘known’ serotype (e.g. AAV2)
decoy capsids are used.
Possible to use higher/lower
ratio of decoy:full capsids
depending on pre-existing
NAb titre
Inclusion of additional decoy capsids
may increase immune responses,
possibly resulting in (i) CD8+ T-
cell activation and destruction of
transduced cells, and (ii) stronger
induction of NAb responses.
Would require production of more
AAV capsids which could create a
manufacturing bottleneck
Medium: AAV vectors (e.g.
AAV2 or 8) used for decoys
have established safety profiles
in humans, but some additional
safety/toxicity studies may be
required as higher overall
capsid titres will be used
Plasmapheresis Effective at reducing pre-
existing NAb levels if multiple
rounds are used. Relatively
non-invasive and safe
procedure; routinely used in
other applications to deplete
antibody levels
May not be effective if pre-existing
titres are very high. ‘Rebound’
phenomenon may limit
effectiveness and possibility of
repeated use
Low: routinely used for treatment
of autoimmune conditions.




Possible to utilise FDA-






May be ineffective at completely
depleting memory B-cells in the
bone marrow, which may be
required to overcome humoral
immunity. Little evidence the
approach may enable vector
administration in spite of reducing









Effective in preclinical studies at
enabling efficient gene
transfer in low and moderate
NAb titre animals. Clinical
evidence suggests the
approach is safe in patients
undergoing graft rejection
Patients may harbour pre-existing
humoral immunity to, or develop
humoral immunity against this
microbial enzyme. Strategy may
only be partially effective against
high titres of NAbs
Medium: IdeS is not FDA/EMA
approved, however, regulatory
barriers to successful
translation may be lessened
given positive safety data
pertaining to IdeS in the clinic
AAV, adeno-associated virus; NAb, neutralising antibody; PEG, polyethylene glycol; IdeS, an immunoglobulin-cleaving enzyme.
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of naturally occurring AAV isolates or the engineering of
novel AAV vectors.
Approximately 100 naturally occurring AAVs have now
been identified in humans and non-human primates, each
of which harbours a distinct tissue tropism, immunogenicity
and susceptibility to NAbs. AAVrh32.33, for example, was
isolated from Rhesus macaques, and can transduce a variety
of human cell types (Vandenberghe, 2010; Mays et al., 2013),
yet only 2% of humans are thought to harbour pre-existing
NAbs against the virus (Calcedo et al., 2009). Whilst this
may prove helpful in circumventing humoral immunity, it
should be noted that AAVrh32.33 may be highly immuno-
genic when injected intramuscularly, possibly limiting its
application as a gene therapy vector (Mays et al., 2013).
Another natural AAV isolate is AAVrh10, which has been
shown to be largely safe and effective at delivering genes to
the CNS, lung, liver and heart in animal models. One study
reported that 21% of humans are seropositive for AAVrh10,
and harbour pre-existing NAbs against this virus, which is
lower than that reported for AAV2 (20–90% humans are
seropositive), for example, suggesting that AAVrh10 may
be an effective means of transferring genes to patients refrac-
tory to AAV2-based gene therapies (Thwaite et al., 2015).
Ancestral sequence reconstruction (ASR) via phylogenetic
analysis of AAV capsid sequences has also been proposed
as a tool for identifying ancestral AAVs with favourable vec-
tor immunobiology properties. Anc80L65 is one such vector
that is an ancestor of AAVs 1, 2, 8 and 9, and can deliver
genes to the retina, liver, and muscle. Analysis of the struc-
ture and sequence alignment of Anc80L65 with extant AAVs
demonstrated that Anc80L65 was structurally distinct from
AAV2, 8 and rh10, exhibiting 12.2, 9.1 and 8.6% cap
sequence divergence respectively. As a result, it was found
that the vector was significantly more resistant to neutralisa-
tion by cross-reactive anti-AAV2 and anti-AAV8 sera than
AAV2 and AAV8 vectors. However, in an in vivomodel utilis-
ing an initial intravenous injection and sequential intramus-
cular injection, escape from neutralisation was only
observed in 3/5 animals tested. Overall, Anc80L65 is a
promising candidate vector for circumventing humoral
immunity (Zinn et al., 2015).
Other means of engineering the AAV capsid to overcome
neutralisation by NAbs involves the modification of antigenic
epitope regions on the capsid surface, using molecular biology
techniques like error-prone polymerase chain reaction (PCR)
and DNA shuffling, to generate diverse capsid libraries which
can subsequently be screened for capsids resistant to neutralisa-
tion by anti-AAV NAbs (Kotterman & Schaffer, 2014).
An early demonstration of the potential of this approach
was reported in 2008, when an adapted DNA family shuf-
fling technology was used to create hybrid AAV capsid pro-
teins. Two rounds of selection were used. The first used
in vitro hepatocyte cultures to identify AAVs effective at trans-
ducing target cells. Pooled human immunoglobulin G (IVIg)
was then used to isolate an AAV2/8/9 chimera, termed
AAV-DJ, that was found to be more resistant to NAbs than
AAV2 in IVIg-immunised mice (Grimm et al., 2008).
This approach was explored further to identify AAV cap-
sids that were resistant to neutralisation. A number of AAV
capsid libraries were utilised, including a randomly mutagen-
ised AAV2 library, an AAV2 library with specific residues
subject to saturation mutagenesis, a ‘shuffled’ AAV cap
library (generated from AAVs 1, 2, 4, 5, 6, 8, and 9), and
an AAV library in which surface hypervariable loops had
been swapped between serotypes. Two rounds of selection
were then used to identify AAV capsids resistant to neutrali-
sation by NAbs by IVIg and sera samples from patients
excluded from haemophilia B clinical trials harbouring
high-titre AAV NAbs. The authors conclude that the novel
AAV capsids generated may be used to treat patients with
high titres of pre-existing NAbs and repeated gene transfer
(i.e. re-administration of a gene therapy) in patients who have
developed NAbs against AAV (Bartel, Weinstein &
Schaffer, 2012).
Aside from directed evolution, AAVs can also be rationally
designed via the mutagenesis of epitope regions. This first
requires the identification of regions important for binding/
neutralisation by antibodies. One method utilises peptide
scanning, in which short linear epitopes are used in
enzyme-linked immunosorbent assay (ELISA) screens to
identify capsid proteins that bind to anti-AAV antibodies.
Peptide insertion into AAV capsids can also be used to dis-
rupt NAb epitopes and thereby identify antibody binding
regions on the vector (Tse, Moller-Tank & Asokan, 2015).
In silico modelling and systematic mutagenesis of IgG2a anti-
bodies to AAV2 has also been used to identify residues
important for antibody binding (Wu et al., 2014). These dis-
coveries have aided the development of NAb-resistant AAVs
using a structure-guided approach that does not require the
use of IVIg or high NAb titre patient sera to exert selective
pressures on large capsid libraries for identifying resistant
clones. In one report, synthetic AAVs were evolved via ratio-
nal mutation of AAV1 antigenic epitopes, which were found
to evade polyclonal anti-AAV1 neutralising sera without
impacting the tissue tropism or transduction efficiency of
the vectors in mouse models and non-human primates (Tse
et al., 2017).
Whilst most modifications to AAV to improve NAb resis-
tance have focussed on modification of cap gene/capsid pro-
tein sequences, recent reports have shown that the
encapsulation of AAVs in exosomes can also reduce their sus-
ceptibility to humoral immune responses. Termed exosome-
associated AAV (exoAAV), these novel vectors have demon-
strated improved transduction across a range of cell types
and tissues, in addition to enhanced resistance to NAbs in
IVIg-immunised mice. This reduced sensitivity to NAbs has
been shown for exoAAV8 in the liver (Meliani et al., 2017)
and exoAAV9 in the CNS (Hudry et al., 2016).
(c) Chemical modification of AAV
The engineering of AAV to avoid neutralisation by NAbs has
resulted in the development of exciting novel vectors capable
of circumventing humoral immune responses via the
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disruption of antigenic epitopes. An alternative approach to
preventing NAb-AAV binding/neutralisation is to shield epi-
topes via chemical modification of AAVs.
Polyethylene glycol (PEG) can be chemically conjugated to
AAVs to mask them from NAbs, for example. Whilst PEG-
coated AAVs have been shown to exhibit greater resistance
to NAb-mediated neutralisation, it should be noted that only
partial protection was inferred via this chemical modification.
It was also noted by the authors that the addition of PEG
above a certain threshold attenuated the AAVs transduction
potential, likely via steric hindrance between cell surface
receptors and cognate AAV capsid proteins (Lee et al., 2005).
Alternative approaches have sought to encapsulate AAVs
in polymer gels like polylactic glycolic acid and alginate that
gradually degrade in vivo. This approach has been applied to
adenoviruses (Beer et al., 1998; Sailaja et al., 2002) and has
shown to increase the resistance of these vectors to NAbs,
suggesting that this approach may also be effective for AAV
vectors. However, the development of anti-polymer antibody
responses may pose a significant challenge to this technology
(Hoang Thi et al., 2020).
(d) Use of decoy capsids
The use of decoy capsids to circumvent anti-AAV NAbs
involves the administration of empty capsid AAVs or
infection-deficient AAVs to sequester NAbs prior to or at
the same time as therapeutic vector administration. In non-
human primates, this approach has been shown to block cir-
culating NAbs competitively in a dose-dependent manner
and concomitantly restore transduction efficiency (Mingozzi
et al., 2013b), however, other studies have shown that this
approach is not always effective at circumventing humoral
immune responses (Monahan et al., 2015). The authors also
showed that the presence of empty capsids in their AAV8
vector preparations did not prevent neutralisation of FIX.
R338L delivery in their models via a so-called ‘decoy capsid’
action (Mingozzi et al., 2013b; Monahan et al., 2015). In con-
trast to previous reports, which utilised IVIg (Mingozzi
et al., 2013b), Monahan et al. (2015) opted for a passive trans-
fer strategy involving the generation of anti-AAV8 NAbs in
one group of mice which were then collected and transferred
to a different group of mice receiving the FIX.R338L gene
therapy. The authors reported that 1:2 or 1:16 NAb titres
were sufficient to attenuate transfer of FIX.R338L, but this
effect was not rescued by the inclusion of empty capsids in
the AAV8 preparation. This was in opposition to previous
findings suggesting that ‘decoy capsids’ may be an effective
means of circumventing anti-AAV NAbs (Mingozzi
et al., 2013b). Several key differences between these studies
are evident, however. First, the source of NAbs [use of hIVIg
(Mingozzi et al., 2013b) versus passive transfer of mouse sera
(Monahan et al., 2015)] is a key disparity. Further, in Min-
gozzi et al. (2013b), a higher ratio of decoy vector to full vector
was used, both of which may explain the different outcomes.
The use of capsid decoys may represent a possible strategy
for overcoming NAb responses, however, this approach may
have certain drawbacks. The inclusion of empty capsids in
vector formulations has been shown to reduce transduction
efficiency and increase vector-related immunotoxicity in
one study investigating liver gene transfer with AAV8 (Gao
et al., 2014), however, in a non-human primate study investi-
gating AAV2-mediated gene delivery to the retina, the
removal of empty capsids had no detectable impact on the
generation of anti-AAV lymphocyte or NAb responses
(Timmers et al., 2020).
(e) Plasmapheresis
Plasmapheresis is a clinical procedure that involves ex vivo
removal of NAbs from an individual’s blood by using
filtration- or centrifugation-based techniques, before the
blood is transferred back (Derksen et al., 1984). The approach
can be used to reduce the build-up of antibodies in conditions
like haemorrhagic lupus pneumonitis (Erickson, Franklin &
Emlen, 1994) and Guillain-Barre syndrome (Buzzigoli
et al., 2010), both of which involve elevated levels of patho-
logic antibodies. It is also used in patients with visual loss
from atypical optic neuropathies mediated by antibodies
against aquaporin-4 (AQP4) and myelin oligodendrocyte
glycoprotein (MOG) (Sato et al., 2014). In terms of gene ther-
apy, plasmapheresis provides a possible means of achieving a
transient drop in NAb titres below a certain threshold to
enable vector administration. It could, therefore be applied
to an individual with high pre-existing NAb levels or one
who develops high NAb titres after receiving a gene therapy.
This approach was tested in a non-human primate model,
and found to be effective with six rounds of plasmapheresis
over a 2-day period effectively reducing NAb levels in sero-
positive animals. Following vector administration, animals
that had undergone plasmapheresis exhibited the same trans-
duction levels as seronegative animals following intravenous
injection of a microDystrophin-expressing AAV construct
(Chicoine et al., 2014). Plasmapheresis is usually well toler-
ated from a safety perspective (Vucic & Davies, 1998). How-
ever, one possible limitation to using plasmapheresis is a
phenomenon known as ‘rebound’, in which IgG levels
quickly return to the same or even higher levels following
treatment. In a clinical trial, it was shown that multiple
rounds of plasmapheresis were required to reduce NAb levels
for gene therapy, which could be partly explained by this
‘rebound’ effect. Whilst reductions to <1:5 NAb titres were
achieved in some individuals across multiple serotypes
(AAV1, 2, 6 and 8), it should be noted that such an outcome
required five rounds of plasmapheresis in some instances.
Furthermore, in those individuals exhibiting very high pre-
existing NAb titres, for example, 1:12800 anti-AAV2 in one
particular case, successive rounds of plasmapheresis did not
reduce the titre below 1:200. This suggested that the process
may be ineffective in enabling efficient gene transfer in all
patients with pre-existing NAbs (Monteilhet et al., 2011).
Recently, a novel plasmapheresis protocol was described,
in which the specific depletion of anti-AAV IgG from plasma
could be achieved without depleting total IgG levels. Using
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this approach, high-titre human IgG pools and plasma sam-
ples were tested, and near-complete removal of anti-AAV
IgGwas achieved using anN-hydroxysuccinimidyl sepharose
column onto which AAV8 particles were grafted. The process
was able to reduce anti-AAV8 IgG to levels that enabled effi-
cient gene transfer in mouse models. This study highlighted
the possible advantages to specific depletion of AAV IgG using
plasmapheresis, which has distinct safety advantages, mitigating
the risks of leaving an individual vulnerable to opportunistic
pathogens following pan-IgG depletion (Bertin et al., 2020).
(f ) Use of pharmacological immunosuppressants
The use of immunosuppressant drugs, which may impact both
the innate and adaptive arms of the immune system, appears to
be largely effective in managing anti-AAV T-cell responses
when administered prophylactically or once a rise in liver trans-
aminases is detected. Completely circumventing pre-existing
anti-AAV humoral immunity with broad-acting immunosup-
pressants is more challenging however, likely due to the inability
of these compounds effectively to deplete memory B-cells in the
bone marrow (Vandamme et al., 2017). One report utilising a
mouse model of AAV immunity has shown that pharmacolog-
ical intervention can be used to reduce pre-existing NAb levels,
however. Pre-existing immunity was generated by an intrave-
nous injection of AAV9 vectors. A combination of rapamycin
and prednisolone administered daily for 8 weeks reduced anti-
AAV9NAb levels by 85–93%, and in addition, decreased levels
of B-cells and plasma cells were observed. This combination
was found to selectively inhibit helper T-cell-mediated B-cell
activation in the spleen, leading to effective anti-AAV9 NAb
depletion. Although such an approach could prove an attractive
strategy for circumventing humoral immune responses to AAV,
this study did not confirm whether vector re-administration was
possible in their model after treatment with rapamycin and
prednisolone (Velazquez et al., 2017).
(g) Use of NAb degrading enzymes
One recent report outlined the possible use of an
immunoglobulin-degrading enzyme, IdeS, to reduce pre-
existing NAb levels and enable efficient gene transfer in
mouse and non-human primate models. The authors showed
that reductions in NAb levels from 1:10 to<1:1 in C57BL6/J
mice was possible following a 25 μg injection of IdeS, which
was associated with increased FIX expression after delivery
of AAV8.FIX, and a concomitant 50% reduction in bleeding
time (measure of therapeutic efficacy in haemophilia B
models). Similarly, in cynomolgus macaques (Macaca fascicu-
laris), a 1:17.2 to <1:5 reduction in NAb titre was achieved
after two injections of 500 μg/kg IdeS. This was associated
with a 4–10-fold increase in FIX levels after delivery of
AAV8.FIX. The authors suggest that the utilisation of IdeS
in human trials may be safe, given that its use has not yet been
associated with significant toxicities or increased risk of
opportunistic infection in healthy subjects (Winstedt
et al., 2015) or patients undergoing graft transplantation
(Jordan et al., 2017). However, the possibility of patients har-
bouring pre-existing humoral immunity to IdeS, or develop-
ing humoral immunity to IdeS following administration, may
require further investigation. The authors tested whether
IdeS could enable repeated gene transfer using sequential
injections of AAV-LK003.FIX. Whilst 10-fold reductions in
NAb levels were seen in some of the non-human primate
models, only two subjects appeared to permit transduction
after the second injection of AAV-LK003, and even in these
animals, the level of FIX peaked at ~100 ng/ml, which is
four times lower than that observed in the IdeS-treated ani-
mal in their earlier experiments. In summary, IdeS appeared
to be effective at circumventing humoral immunity when
faced with low to moderate NAb levels, but may not be
completely effective at overcoming high NAb titres
(Leborgne et al., 2020).
(2) Preventing the induction of AAV NAbs
Pre-existing NAbs represent a significant barrier to the suc-
cess of gene therapies in the clinic. As outlined above, the
delivery of AAV into most, if not all, sites in the body appears
to result in the development of humoral immunity against the
capsid, which may limit the possibility of vector re-adminis-
tration. This is an important aspect of AAV gene therapy
for several reasons. First, gene therapy constructs may display
reduced efficacy over time as cells epigenetically downregu-
late ‘foreign’ gene expression cassettes via CpG island hyper-
methylation (Gray et al., 2011). Second, in dividing tissues
such as the liver, transduced cells are lost over time, thereby
reducing therapeutic efficacy (Verdera et al., 2020). In a num-
ber of non-dividing tissues, such as the inner retina/RGC
layer, many pathologies exhibit a degenerative phenotype
which may lead to the loss of transduced cells over time
(Levin &Gordon, 2002). For many diseases, titrating the vec-
tor dose may prove a useful strategy towards ‘tailoring’ a
gene therapy to a particular patient due to disparities in
age and/or stage of disease progression, for example. In all
of these scenarios, efficient vector re-administration is
required, in which preventing the development of anti-
AAV NAbs is key. Here we will discuss a number of possible
strategies that could be used to achieve this goal in clinical tri-
als and preclinical studies. These are summarised in Table 4.
(a) Inhibition of T-cell activation
CD4+ ‘helper’ T-cells can indirectly affect the humoral
immune response by regulating the function of B-cells and
their antibody-producing progeny plasma cells. Downregu-
lating CD4+ T-cell function can therefore be utilised as a
means of reducing anti-AAV NAb levels. The promising
results discussed below suggest that the inhibition of T-cell
activity could prove an effective means of preventing the
induction of anti-capsid humoral immune responses in
the eye.
Anti-CD4 antibodies have been used to deplete (via induc-
tion of apoptosis in target cells) CD4+ T-cell levels and
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abolish anti-AAV NAb levels following a tail vein injection of
AAV in a mouse model. However, this study also demon-
strated that delivery of the vector directly into the portal cir-
culation produced a humoral immune response that was only
partially T-cell-dependent, thereby reducing the effective-
ness of the anti-CD4 depletion strategy. Overall the study
demonstrated that CD4 depletion may be an effective means
of circumventing NAb responses for certain routes of delivery
(Xiao et al., 2000).
Alternative approaches have described the use of non-
depleting anti-CD4 antibodies to prevent NAb responses.
Here, intravenous administration of an anti-CD4 monoclo-
nal antibody (mAb) prior to delivery of an AAV2/9 vector
demonstrated reductions in anti-vector and anti-transgene
[acid α-glucosidase (GAA)] NAbs in a mouse model of
Pompe disease. The authors concluded that the mAb pre-
vented co-receptor (CD4) stimulation of T-cells, in turn ren-
dering them ineffective as B-cell activators (Han et al., 2015).
T-cell-dependent activation of B-cells can also be inhibited
by blocking other signalling pathways. Antibodies and fusion
proteins against CD40-CD40L and CD28-CD80/86 recep-
tors have been shown to reduce NAb levels against AAV pro-
teins and thereby enable re-administration to the lung in a
rabbit model (Halbert et al., 1998). One study sought to
combine a non-depleting anti-CD4 mAb therapy with the
T-cell immunosuppressive drug, cyclosporin A (CyA), and
showed that a 20-fold reduction in NAb levels was possible
using this approach (McIntosh et al., 2012). Other studies
have utilised ‘Tregitopes’ (De Groot et al., 2008) (IgG-
derived MHC epitopes) to activate Treg responses in order
to inhibit NAb production. In a mouse model, Tregitopes
were fused to AAV capsid peptides, and subsequently used
to induce proliferation of Treg cells that suppressed CD8+
T-cell cytotoxic function against AAV-expressing cells (Hui
et al., 2013). This demonstrated an interesting proof-of-
concept and suggests that Tregitopes could be applied to
reducing NAb levels after vector administration.
(b) Inhibition of B-cell activation
The inhibition of T-cell activation can prevent anti-AAV
antibody production by B-cells/plasma cells. Efforts to
inhibit activation and/or induce apoptosis of B-cell/plasma
cells have also shown promise as tools for overcoming
humoral immunity to AAV. The activation of B-cells and
their maturation into antibody-producing plasma cells is a
complex process. With AAV gene therapy, APCs are thought
to display AAV capsid peptides to immature B-cells which
Table 4. Summary of possible strategies to prevent induction of anti-AAV Nabs
Strategy Advantages Disadvantages Translational barriers
Inhibit T-cell activation Several pathways can be targeted
to prevent anti-AAV NAb
responses using FDA-approved
drugs such as Cedelizumab.
Tregitopes may be used to
induce tolerance of AAV
antigens









anti-CD4 mAbs are available
for creating
immunosuppression in
patients. Few clinical data
supporting safety of approach
in humans
Inhibit B-cell activation Inhibiting B-cell function may
prevent NAb formation whilst
retaining cytotoxic T-cell
function, against tumourigenic
cells for example. FDA-
approved drugs are available
for this application. Preclinical
evidence suggests generation of
tolerogenic B-cells is possible
B-cell levels may take 6–











anti-CD20 mAbs are available
for creating
immunosuppression in
patients. Few clinical data




Possible to utilise FDA-approved






this approach may not be
sufficient to prevent NAb
formation or enable
vector re-administration.
Outcomes of clinical trials
investigating gene
delivery to the retina also
suggest this approach may
not be effective in all
patients
Low: many immunosuppressants
are FDA-approved and are




AAV, adeno-associated virus; NAb, neutralising antibody.
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initiate downstream signalling pathways resulting in the
endocytosis of AAV antigens (Carrasco & Batista, 2006; Har-
wood & Batista, 2008). The B-cell then presents the antigen
on its surface with MHC class II molecules, which can be
recognised by CD4+ helper T-cells, causing them to prolifer-
ate and migrate to the germinal centres, where somatic
hypermutation and isotype switching occur. Most activated
B-cells will become plasma cells and produce NAbs against
AAV, whilst others develop into memory B-cells (Basner-
Tschakarjan, Bijjiga & Martino, 2014). Inhibition of B-cell
activation for circumventing humoral immune responses to
AAV capsids has shown promise in a number of preclinical
models, highlighting possible application to ocular gene ther-
apy programmes.
Understanding the process by which B-cells are activated
therefore helps to inform strategies to prevent NAb
responses. Bortezomib, an FDA-approved therapy for multi-
ple myeloma (plasma cell tumour), is a proteasome inhibitor
that attenuates antigen processing and presentation of epi-
topes on the surface of B-cells. Administration of Bortezomib
has been shown to reduce NAb titres by 8–10-fold by deplet-
ing AAV2/8-specific IgG-producing plasma cells in the lym-
phoid organs and bonemarrow. However, this reduction was
not sufficient to allow vector re-administration, which the
authors attribute to residual anti-AAV8 NAbs due to the
inability of Bortezomib completely to eradicate anti-AAV8
plasma and memory B-cells (Karman et al., 2012).
Depletion of activated B-cells can also be utilised as a
means of reducing NAb levels. Rituximab, an anti-CD20
antibody, can induce B-cell apoptosis by (i) recruiting cyto-
toxic natural killer and macrophage cells to antibody-bound
B-cells, or (ii) activating the cytotoxic complement cascade via
C1q binding to induce B-cell lysis (Smith, 2003). In a clinical
trial, Rituximab treatment was shown to reduce circulating
NAb levels up to 24 weeks after two intravenous infusions,
however the authors noted that these reductions were only
observed in a subset of patients with titres of <1:1000, and
only a minority of subjects’ titres were reduced to <1:5
(Mingozzi et al., 2013a). This finding was corroborated by
reports that a combination of rituximab and rapamycin in
a 45-month-old patient with Pompe disease was an effective
strategy to mitigate anti-AAV immune responses. The
authors conclude that the strategy allows for the possibility
of vector re-administration in the future, but no data were
presented in relation to this, and it should also be noted that
this was a single-subject clinical trial (Corti et al., 2014). In a
non-human primate study, CyA (calcineurin inhibitor,
inhibits T- and B-cells) was trialled in combination with
Rituximab. The study showed that anti-transgene (FIX for
haemophilia B) NAb levels could be significantly reduced
with this strategy. Further, in one animal, anti-AAV6 NAb
titres dropped to undetectable levels, which was subsequently
shown to be permissive of vector re-administration. In the
other animal however, the dual immunosuppression strategy
did not appear to be effective and re-administration
appeared to be blocked by anti-AAV6 NAbs (Mingozzi
et al., 2012).
Clearly, B-cell depletion strategies may be an effective
means of overcoming humoral immunity to AAV, however,
the approach is not without its drawbacks. For instance, fol-
lowing Rituximab treatment, patients are immunocompro-
mised for a period of around 6–12 months as their B-cell
levels return to normal, which can leave them vulnerable to
opportunistic pathogens. In two severe cases, activation of
dormant human polyomavirus was associated with the onset
of progressive multifocal leukoencephalopathy following
administration of Rituximab (Chakraborty et al., 2011). Fur-
ther, it should be noted that anti-CD20 antibodies will not
deplete plasma cells, which are the antibody-producing cells
of the immune system, possibly limiting the ability of the
strategy to reduce NAb levels whilst still posing a significant
safety concern (Leandro, 2013).
As an alternative to B-cell depletion, the induction of B-
cell tolerance can be utilised to prevent the generation of
anti-AAV NAbs and thereby allow for vector re-adminis-
tration. For instance, antigen-specific immunotherapy
can be used to inhibit B-cell activation by inducing Treg
cells for a particular antigen. In one study, an immuno-
genic protein was fused to an immunoglobulin heavy
chain, and transferred into activated B-cells in vitro using
a retroviral vector. The generation of tolerogenic B-cells
was observed which were found to attenuate immune
responses against multiple epitopes of the cloned protein.
Mechanistically, this effect was linked to the stimulation
of Treg cells by the transduced B-cells (Skupsky
et al., 2007). Whilst this approach has not yet been applied
to AAV gene therapy, these results suggest it might be
effective at limiting humoral immune responses.
Another means of preventing B-cell activation is to target
inhibitory co-receptors present on the surface of B-cells.
CD22 and SIGLEC-G are two sialic acid-binding co-receptors
known to play a role in mediating the induction of tolerance of
self-antigens. Recent data have shown that high-affinity ligands
for these co-receptors can induce antigen-specific B-cell toler-
ance, highlighting a possible strategy for treating autoimmune
diseases which may be applied to preventing anti-AAV
humoral immune responses in the future (Müller &
Nitschke, 2014). For instance, immunisation of mice with
nanoparticles conjugated to human factor VIII and CD22
has been shown to induce tolerance to and antibody produc-
tion against factor VIII (Macauley et al., 2013), suggesting a
similar approach could be applied to AAV capsid proteins.
(c) Use of pharmacological immunosuppressants
In addition to targeting specific arms of the immune system
with anti-CD4 or anti-CD20 antibody-based depletion strat-
egies, the use of broad-acting small molecule immunosup-
pressants has been trialled, either alone or in combination.
Many of these are FDA-approved and routinely used in
patients, making this approach highly clinically translatable
for ocular gene therapy.
In a mini-pig model of advanced heart failure, AAV1
encoding sarcoplasmic reticulum calcium ATPase gene
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(SERCA2a) was delivered by intravenous administration. A
combination of immunosuppressive drugs was tested to see
whether this could circumvent NAb responses. Here, oral
mycophenolate mofetil (MMF) and rapamycin were admin-
istered daily from 2 weeks before to 3 months after vector
infusion, and methylprednisolone sodium succinate was
administered daily by intramuscular injection up to 3 months
after AAV1 delivery. In spite of the utilisation of this aggres-
sive immunosuppressive regimen, the induction of AAV1
NAbs was still observed in both the immunosuppressed and
non-immunosuppressed groups, and comparison of these
groups revealed no apparent effect of immunosuppression
on the development of NAbs (Greenberg et al., 2016).
Studies examining immunosuppression in non-human pri-
mates have suggested the approach may not be effective for
liver gene therapy with AAV5. Here, animals were injected
intravenously with AAV5 to generate an immune response.
Over the next 12-week period, anti-thymocyte IgG, methyl-
prednisolone, tacrolimus and rituximab were given in combi-
nation. These were found to attenuate anti-AAV5 NAbs
during the 12 weeks, but NAb levels rose significantly once
this treatment stopped. The authors then demonstrated that
this ‘rebound’ in NAb levels completely inhibited repeated
vector re-administration of AAV5 (Unzu et al., 2012).
These results were corroborated by another study in non-
human primates investigating microDystrophin delivery to
the muscle. Animals receiving (i) prednisolone alone, (ii) a
prednisolone, tacrolimus and MMF combination, and (iii)
no immunosuppressants were compared. No differences in
transgene expression were observed in seropositive animals
between these three groups, indicating that the immuno-
suppressants given may have been ineffective at reducing
anti-AAV NAb levels. This was in spite of the fact that the
immunosuppressants were shown to downregulate lympho-
cyte proliferation, a finding which may highlight the chal-
lenge in attenuating pre-existing humoral immunity to
AAV (Chicoine et al., 2014).
The complexity of overcoming the induction of NAbs
against AAV following delivery to the CNS has been demon-
strated in clinical studies. One study tested an AAV2 vector
expressing aspartoacylase and delivered by intracranial
injection in patients with Canavan disease. In this study, only
3/10 patients developed low to moderate sera NAb titres ver-
sus baseline, in spite of the fact that no patients were given
perioperative immunosuppressants (McPhee et al., 2006).
In another trial, an AAVrh10 vector encoding arylsulpha-
tase A was delivered by intracerebral injection in patients
with metachromatic leukodystrophy. Steroids were adminis-
tered 1 day prior and 10 days after the surgery, however, in
all patients enrolled in the study, the development of anti-
AAV antibodies was observed in the sera and CSF. This sug-
gestion that steroids may not be effective in preventing anti-
AAV NAb responses has been supported by recent data
investigating AAV9 gene therapy. Here, AAV9 vectors were
used to transfer gigaxonin into the CNS of cross-reactive
immunologic material (CRIM)-negative giant axonal neu-
ropathy patients, and a combination of methylprednisolone,
prednisone, tacrolimus and rapamycin was used. However,
anti-AAV9 NAbs were still observed in the sera and CSF
after vector infusion, in spite of the fact that the combination
of immunosuppressants was effective at preventing inflam-
mation (pleocytosis; elevated CSF lymphocyte counts)
(Verdera et al., 2020). This is possibly in accordance with clin-
ical studies investigating AAV gene transfer to the retina
reviewed above in which some patients developed NAb
responses in the absence of intraocular inflammation.
Recently, small molecule immunosuppressants have been
modified to improve their properties in vivo. In a study utilis-
ing non-human primate and mouse models, rapamycin was
encapsulated in poly-lactic acid nanoparticles, termed SVP
rapamycin (rapa). SVPrapa was found to prevent anti-AAV
cellular and humoral immune response induction, thereby
permitting re-administration of the vector, when co-
administered with the initial injection of AAV. The drug mit-
igated antigen-specific activation of T-cells and B-cells, pre-
vented CD8+ T-cell infiltration into the liver, and inhibited
memory T-cell responses. Interestingly, the authors showed
that the adoptive transfer of splenocytes from treated to nai-
ive mice transferred the immunomodulatory properties of
SVPrapa. They then demonstrated that anti-CD25 antibody
depletion partially rescued SVPrapa’s effect on anti-AAV8
IgG levels, suggesting that Treg cells may be involved in
the mechanism of action (Meliani et al., 2018).
(3) Overcoming humoral immune responses to AAV
– the need for a comprehensive approach
The studies discussed above highlight the possible challenges
of circumventing humoral immune responses to AAV. It is
clear that some approaches have shown promise in preclini-
cal models and human patients. In our view, however, effec-
tive strategies to overcome pre-existing NAbs and prevent
the induction of humoral immunity against AAV gene thera-
pies are still under development. A summary of possible
advantages, disadvantages and barriers to clinical implemen-
tation for each approach is provided in Tables 3 and 4. Here
we will suggest a comprehensive strategy that could be used
to circumvent both pre-existing and induced humoral immu-
nity in the future. We aim to provide a framework for future
investigations so that robust and repeatable vector adminis-
tration to previously untreatable patients is possible. Our
proposed approach is outlined in Fig. 2.
Completely to eliminate pre-existing humoral immunity
against AAV, especially if a patient presents with a high
NAb titre, may require a combinatorial approach. AAV-
specific plasmapheresis may initially be used to reduce NAb
titres, followed by a vector infusion incorporating a novel
vector with either (i) mutated capsid epitopes (via a random
or computational approach), (ii) NAb-resistant chemical
modifications, or (iii) a combination of both. The inclusion
of decoy capsids may also be utilised to sequester any NAbs
that were not cleared by plasmapheresis. In conjunction, a
combination of broad-acting small molecule immunosup-
pressants may be administered perioperatively, along with a
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Fig 2. Possible approaches to enable repeated gene transfer. Top panel: an individual with a high pre-existing NAb titre that results
in neutralisation of conventional AAV serotypes in the absence of immunomodulation. Bottom panel: Pre-existing NAbs are depleted
and immunomodulation is used to reduce induction of anti-AAV NAbs post-administration. Patient sera is extracted and used to
screen an AAV library for NAb-resistant and target tissue-tropic clones. This enables repeated gene delivery to multiple organs in
a patient presenting with multiple morbidities. AAV, adeno-associated virus; BP, bipolar cell; IS, immunosuppression; PR,
photoreceptor; RGC, retinal ganglion cell; RPE, retinal pigment epithelium; NAb, neutralising antibody.
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T- or B-cell-targeted peptide immunotherapy approach to
induce antigen-specific tolerance to an AAV antigen and pre-
vent the induction of anti-AAV NAbs that may arise in
response to certain gene therapies.
This example, whilst hypothetical, demonstrates the range
of possible solutions currently under investigation and high-
lights the need for a range of approaches to ensure efficient
and repeatable vector administration to target organs. How-
ever, there is a need for more research into what combination
of possible solutions provides maximal benefit depending on
the target organ and route of administration. In particular,
investigation into possible redundant or counterproductive
combinations (e.g. effective T-cell/B-cell depletion negating
the need for small molecule immunosuppressants, or success-
ful capsid modifications eliminating the use of decoy capsids).
Further studies are also needed to establish safety and effi-
cacy profiles of novel vectors in particular, which will require
regulatory approval before routine clinical use is feasible. In
the future, a library of FDA-approved, antigenically distinct
engineered AAVs with highly specific tissue tropisms would
likely be beneficial, which may enable repeated ‘swapping’
of vector capsids for a particular therapeutic construct to
overcome pre-existing and/or induced humoral immunity
whilst ensuring robust and tissue/cell-specific transduction.
Here, high-throughput NAb assays could enable selection
of an AAV variant from a library that is resistant to neutrali-
sation by a particular patient’s sera. A peptide scanning
based-approach (Moskalenko et al., 2000) could even be used
subsequently to identify epitopes on the selected capsid, allow
rational mutagenesis of these regions and ensure maximal
resistance of the engineered virion to neutralisation, and to
facilitate ‘individualised’ gene delivery to a particular patient
based on a thorough characterisation of their NAbs.
VI. CONCLUSIONS
(1) AAV is a promising vector for delivering therapeutic
genes to diseased cells. A number of clinical trials have
shown that AAV is a safe and effective vehicle for gene
therapy, however, the deleterious role of NAbs
remains a significant barrier in a proportion of treated
individuals.
(2) Pre-existing NAbs limit the efficiency of gene transfer
to the cells being targeted with a potential negative
impact on treatment efficacy. This is an especially
important consideration for strategies that involve
intravenous AAV infusions into the circulation where
very low or even undetectable NAb titres may
completely abolish transduction of the target tissues.
Injections of AAV into skeletal muscle and the CNS,
including the retina, also appear to be partially limited
by pre-existing NAbs.
(3) After vector administration, an increase in AAV NAbs
has been documented in some individuals recruited
into clinical trials investigating muscular, hepatic and
neurological disorders. In the ocular compartment,
the increased NAb titres observed after IVT or SRT
does not appear to be correlated with the vector dose
or baseline NAb titre. Interestingly, intraocular
inflammation appears to be more common in those
individuals who do exhibit significant increases in
NAb titres. More research is, therefore, needed to
understand why this particular subgroup exhibit
greater NAb responses, with early evidence pointing
towards AAV reactive T-cells playing a role in these
seronegative individuals. The longevity of the thera-
peutic effect of AAV vectors in individuals with intra-
ocular inflammation could be monitored with long-
term follow-up, as this group may be most at risk of
CD8+ T-cell clearance of transduced cells and even-
tual loss of efficacy.
(4) In our view, circumventing AAV NAbs to enable
repeated dosing to multiple organs, including the ret-
ina, will require a comprehensive strategy capable of
overcoming both pre-existing and induced humoral
immune responses. More research is also required to
understand whether prophylactic steroid administra-
tion prevents NAb induction, and the application of
other T-cell and B-cell immunomodulators to block
this critical step could also prove beneficial. To over-
come pre-existing high titres of NAbs, the potential
application of plasmapheresis and decoy capsids prior
to intraocular injection requires further evaluation.
Utilising patient sera to select NAb-resistant clones
from a capsid library, followed by rational mutation
of capsid epitopes could prove a useful strategy in the
future, enabling individualised intraocular gene deliv-
ery to a particular individual.
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